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A B S T R A C T
Background
Knee osteoarthritis is a leading cause of chronic pain, disability, and decreased quality of life. Despite the long-standing use of intra-
articular corticosteroids, there is an ongoing debate about their benefits and safety. This is an update of a Cochrane review first published
in 2005.
Objectives
To determine the benefits and harms of intra-articular corticosteroids compared with sham or no intervention in people with knee
osteoarthritis in terms of pain, physical function, quality of life, and safety.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE (from inception to 3
February 2015), checked trial registers, conference proceedings, reference lists, and contacted authors.
Selection criteria
We included randomised or quasi-randomised controlled trials that compared intra-articular corticosteroids with sham injection or no
treatment in people with knee osteoarthritis. We applied no language restrictions.
Data collection and analysis
We calculated standardised mean differences (SMDs) and 95% confidence intervals (CI) for pain, function, quality of life, joint space
narrowing, and risk ratios (RRs) for safety outcomes. We combined trials using an inverse-variance random-effects meta-analysis.
Main results
We identified 27 trials (13 new studies) with 1767 participants in this update. We graded the quality of the evidence as ’low’ for all
outcomes because treatment effect estimates were inconsistent with great variation across trials, pooled estimates were imprecise and did
not rule out relevant or irrelevant clinical effects, and because most trials had a high or unclear risk of bias. Intra-articular corticosteroids
appeared to be more beneficial in pain reduction than control interventions (SMD -0.40, 95% CI -0.58 to -0.22), which corresponds
to a difference in pain scores of 1.0 cm on a 10-cm visual analogue scale between corticosteroids and sham injection and translates
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into a number needed to treat for an additional beneficial outcome (NNTB) of 8 (95% CI 6 to 13). An I2 statistic of 68% indicated
considerable between-trial heterogeneity. A visual inspection of the funnel plot suggested some asymmetry (asymmetry coefficient -
1.21, 95%CI -3.58 to 1.17). When stratifying results according to length of follow-up, benefits were moderate at 1 to 2 weeks after
end of treatment (SMD -0.48, 95% CI -0.70 to -0.27), small to moderate at 4 to 6 weeks (SMD -0.41, 95% CI -0.61 to -0.21), small
at 13 weeks (SMD -0.22, 95% CI -0.44 to 0.00), and no evidence of an effect at 26 weeks (SMD -0.07, 95% CI -0.25 to 0.11). An
I2 statistic of ≥ 63% indicated a moderate to large degree of between-trial heterogeneity up to 13 weeks after end of treatment (P
for heterogeneity≤0.001), and an I2 of 0% indicated low heterogeneity at 26 weeks (P=0.43). There was evidence of lower treatment
effects in trials that randomised on average at least 50 participants per group (P=0.05) or at least 100 participants per group (P=0.013),
in trials that used concomittant viscosupplementation (P=0.08), and in trials that used concomitant joint lavage (P≤0.001).
Corticosteroids appeared to be more effective in function improvement than control interventions (SMD -0.33, 95% CI -0.56 to -
0.09), which corresponds to a difference in functions scores of -0.7 units on standardised Western Ontario and McMaster Universities
Arthritis Index (WOMAC) disability scale ranging from 0 to 10 and translates into a NNTB of 10 (95% CI 7 to 33). An I2 statistic of
69% indicated a moderate to large degree of between-trial heterogeneity. A visual inspection of the funnel plot suggested asymmetry
(asymmetry coefficient -4.07, 95% CI -8.08 to -0.05). When stratifying results according to length of follow-up, benefits were small to
moderate at 1 to 2 weeks after end of treatment (SMD -0.43, 95% CI -0.72 to -0.14), small to moderate at 4 to 6 weeks (SMD -0.36,
95% CI -0.63 to -0.09), and no evidence of an effect at 13 weeks (SMD -0.13, 95% CI -0.37 to 0.10) or at 26 weeks (SMD 0.06, 95%
CI -0.16 to 0.28). An I2 statistic of ≥ 62% indicated a moderate to large degree of between-trial heterogeneity up to 13 weeks after
end of treatment (P for heterogeneity≤0.004), and an I2 of 0% indicated low heterogeneity at 26 weeks (P=0.52). We found evidence
of lower treatment effects in trials that randomised on average at least 50 participants per group (P=0.023), in unpublished trials (P=
0.023), in trials that used non-intervention controls (P=0.031), and in trials that used concomitant viscosupplementation (P=0.06).
Participants on corticosteroids were 11% less likely to experience adverse events, but confidence intervals included the null effect (RR
0.89, 95% CI 0.64 to 1.23, I2=0%). Participants on corticosteroids were 67% less likely to withdraw because of adverse events, but
confidence intervals were wide and included the null effect (RR 0.33, 95% CI 0.05 to 2.07, I2=0%). Participants on corticosteroids
were 27% less likely to experience any serious adverse event, but confidence intervals were wide and included the null effect (RR 0.63,
95% CI 0.15 to 2.67, I2=0%).
We found no evidence of an effect of corticosteroids on quality of life compared to control (SMD -0.01, 95% CI -0.30 to 0.28, I2=
0%). There was also no evidence of an effect of corticosteroids on joint space narrowing compared to control interventions (SMD -
0.02, 95% CI -0.49 to 0.46).
Authors’ conclusions
Whether there are clinically important benefits of intra-articular corticosteroids after one to six weeks remains unclear in view of the
overall quality of the evidence, considerable heterogeneity between trials, and evidence of small-study effects. A single trial included in
this review described adequate measures to minimise biases and did not find any benefit of intra-articular corticosteroids.
In this update of the systematic review and meta-analysis, we found most of the identified trials that compared intra-articular corticos-
teroids with sham or non-intervention control small and hampered by low methodological quality. An analysis of multiple time points
suggested that effects decrease over time, and our analysis provided no evidence that an effect remains six months after a corticosteroid
injection.
P L A I N L A N G U A G E S U M M A R Y
Joint corticosteroid injection for knee osteoarthritis
Review question
We searched the literature until 3 February 2015 for studies of the effects on pain, function, quality of life, and safety of intra-articular
(injected into the joint) corticosteroids compared with sham injection or no treatment in people with knee osteoarthritis.
Background
Osteoarthritis is a disease associated with a breakdown of cartilage of the joints, such as the knee. When the joint loses cartilage, the
body responds by growing bone abnormally, which can result in the bone becoming misshapen and the joint painful and unstable.
This can affect physical function and the ability to use the joint.
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Although osteoarthritis is generally thought to be of degenerative rather than inflammatory origin, an inflammatory component may
be present at times. Intra-articular corticosteroids are potent anti-inflammatory agents injected inside the knee joint.
Study characteristics
After searching for all relevant studies to 3 February 2015, we found 27 randomised controlled trials with a total of 1767 participants,
of a duration ranging from two weeks to one year.
Key results
Pain
• People who received intra-articular corticosteroids rated improvement in their pain to be about 3 on a scale of 0 (no pain) to 10
(extreme pain) after 1 month.
• People who received a placebo rated improvement in their pain to be about 2 on a scale of 0 (no pain) to 10 (extreme pain) after 1
month.
Another way of saying this is:
• 44 people out of 100 who receive intra-articular corticosteroids respond to treatment (44%).
• 31 people out of 100 who receive a placebo respond to treatment (31%).
• 13 more people respond to treatment with intra-articular corticosteroids than with placebo (difference of 13%).
Note that these numbers may considerably overestimate the true benefit due to the low quality of the evidence.
Physical function
• People who received intra-articular corticosteroids rated improvement in their physical function to be about 2 on a scale of 0 (no
disability) to 10 (extreme disability) after 1 month.
• People who received a placebo rated improvement in their physical function to be about 1 on a scale of 0 (no disability) to 10 (extreme
disability) after 1 month.
Another way of saying this is:
• 36 people out of 100 who received intra-articular corticosteroids respond to treatment (36%).
• 26 people out of 100 who received a placebo respond to treatment (26%).
• 10 more people respond to treatment with intra-articular corticosteroids than with placebo (difference of 10%).
Note that these numbers may considerably overestimate the true benefit due to the low quality of the evidence.
Side effects
• 13 people out of 100 who used intra-articular corticosteroids experienced side effects (13%).
• 15 people out of 100 who used a placebo experienced side effects (15%).
• 2 more people experienced side effects with placebo than with intra-articular corticosteroids (difference of 2%).
Dropouts because of side effects
• 6 people out of 1000 who used intra-articular corticosteroids dropped out because of side effects (0.6%).
• 17 people out of 1000 who used a placebo dropped out because of side effects (1.7%).
• 11 more people dropped out because of side effects with placebo than with intra-articular corticosteroids (difference of 1.1%).
Side effects resulting in hospitalisation, persistent disability, or death
• 3 people out of 1000 who used intra-articular corticosteroids experienced side effects resulting in hospitalisation, persistent disability,
or death (0.3%).
• 4 people out of 1000 who used a placebo experienced side effects resulting in hospitalisation, persistent disability, or death(0.4%).
3Intra-articular corticosteroid for knee osteoarthritis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• 1 more person experienced side effects resulting in hospitalisation, persistent disability, or death with placebo than with intra-articular
corticosteroids (difference of 0.1%).
Based on the evidence, intra-articular corticosteroids may cause a moderate improvement in pain and a small improvement in physical
function, but the quality of the evidence is low and results are inconclusive. Intra-articular corticosteroids appear to cause as many side
effects as a placebo. However, we do not have precise and reliable information about side effects.
Quality of evidence
We graded the quality of the evidence as low for all of our findings, which means that we have little confidence in these results. This
was because results were generally highly discordant across studies and mainly based on small studies of low quality.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Intra-articular corticosteroid compared with sham injection for osteoarthritis of the knee
Patient or population: participants with osteoarthritis of the knee
Settings: various orthopaedic or rheumatology clinics
Intervention: intra-articular corticosteroid
Comparison: sham injection
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Sham injection Intra-articular corticos-
teroid
Pain intensity
Various pain scales.
(median follow-up: 12
weeks)
-1.8 cm change on 10-
cm VAS1
29% improvement
-2.8 cm change
(1 -1.0 cm, -1.5 to -0.6)
2
46% improvement
(1 17%, 10% to 25%)3
SMD -0.40 (-0.58 to -0.
22)
Predictive interval (-1.20
to 0.40)
1749
(26)
⊕⊕©©
low9
NNTB 8 (95% CI 6 to 13)
4
Function
Various function scales.
(median follow-up: 12
weeks)
-1.2 units on WOMAC
(range 0 to 10)1
21% improvement
-1.9 units on WOMAC
(1 -0.7, -1.2 to -0.2)5
34% improvement
(1 13%, 4% to 22%)6
SMD -0.33 (-0.56 to -0.
09)
Predictive interval (-1.19
to 0.54)
1014
(15)
⊕⊕©©
low9
NNTB 10 (95% CI 7 to 33)
7
Number of participants
experiencing any ad-
verse event
(median follow-up: 17
weeks)
150 per 1000 participant-
years8
134 per 1000 participant-
years
(96 to 185)
RR 0.89 (0.64 to 1.23) 84
(2)
⊕⊕©©
low10
Little evidence of harmful
effect (NNTB not statisti-
cally significant)
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Number of participants
who withdraw because
of adverse events
(median follow-up: 25
weeks)
17 per 1000 participant-
years8
6 per 1000 participant-
years
(1 to 35)
RR 0.33 (0.05 to 2.07) 204
(2)
⊕⊕©©
low10
Little evidence of harmful
effect (NNTB not statisti-
cally significant)
Number of participants
experiencing any seri-
ous adverse event
(median follow-up: 26
weeks)
4 per 1000 participant-
years8
3 per 1000 participant-
years
(1 to 11)
RR 0.63 (0.15 to 2.67) 331
(5)
⊕⊕©©
low10
Little evidence of harmful
effect (NNTB not statisti-
cally significant)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; NNTB: number needed to treat for an additional beneficial outcome; RR: risk ratio; SMD: standardised mean difference; VAS: visual analogue scale; WOMAC: Western
Ontario and McMaster Universities Arthritis Index
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Median reduction as observed across placebo groups in large osteoarthritis trials (see methods section, Nüesch 2009).
2 SMDs were back-transformed onto a 10-cm visual analogue scale (VAS) on the basis of a typical pooled standard deviation (SD) of 2.5 cm in large trials that assessed pain using a VAS
and expressed as change based on an assumed standardised reduction of 0.72 SD units in the control group.
3 Percentage of improvement was calculated based on median observed pain at baseline across control groups of large osteoarthritis trials of 6.1 cm on 10-cm VAS (Nüesch 2009).
4 Absolute response risks for pain in the control groups were assumed 31% (see methods section)
5 SMDs were back-transformed onto a standardised Western Ontario and McMaster Universities Arthritis Index (WOMAC) disability score ranging from 0 to 10 on the basis of a typical pooled
SD of 2.1 in trials that assessed function using WOMAC disability scores and expressed as change based on an assumed standardised reduction of 0.58 SD units in the control group.
6 Percentage of improvement was calculated based on median observed WOMAC function scores at baseline across control groups of large osteoarthritis trials of 5.6 units (Nüesch 2009).
7 Absolute response risks for function in the control groups were assumed 26% (see methods section).
8 Median control risk across placebo groups in large osteoarthritis trials (see methods section, Nüesch 2009).
9 Downgraded (2 levels) because: Most studies that reported this outcome are of high or unclear risk of bias, and statistical heterogeneity is large
10 Downgraded (3 levels) because: 50% or more of the studies that reported this outcome are of high or unclear risk of bias, and the confidence interval of the pooled estimate is wide and
includes the null effect
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B A C K G R O U N D
Description of the condition
Knee osteoarthritis is a leading cause of chronic disability in the
United States (Felson 2000; Felson 2000a). It results from a mul-
titude of both local and systemic factors. Progression of the disease
leads to cartilage degeneration and thinning of the joint surface
with subsequent joint pain and stiffness (Brandt 1996).
Description of the intervention
Intra-articular corticosteroid therapy has been used in knee os-
teoarthritis for over 50 years. The first clinical trial of intra-artic-
ular corticosteroids in knee osteoarthritis was performed in 1958
by Miller and colleagues (Miller 1958). Corticosteroids are avail-
able in both crystalline and non-crystalline forms. The crystalline
triamcinolone and the non-crystalline prednisolone and methyl-
prednisolone are used most frequently. Although this review is re-
stricted to osteoarthritis of the knee joint, intra-articular corticos-
teroids have also been evaluated in osteoarthritis of various other
joints (McColl 2000; Rozental 2000).
How the intervention might work
Although osteoarthritis is generally thought to be of degenerative
rather than inflammatory origin, there is evidence that an inflam-
matory component may be present in at least some phases of the
disease (Creamer 1997). Corticosteroids are known as potent anti-
inflammatory agents that act through a variety of mechanisms on
different cellular levels.
Why it is important to do this review
The 2012 American College of Rheumatology (ACR) guidelines
recommend the participation in exercise programs aswell asweight
loss (for overweight patients) as first-line treatments for symp-
tomatic knee osteoarthritis. There is no strong recommendation
for any pharmacological treatment other than over-the-counter
paracetamol or nonsteroidal anti-inflammatory drugs. However,
for people unresponsive to the basic treatment, there is a condi-
tional, weak recommendation for the use of intra-articular corti-
costeroids (Hochberg 2012). Despite the long-standing use of in-
tra-articular corticosteroids, there is an ongoing debate about their
effectiveness and safety. Concerns have been expressed that intra-
articular corticosteroids might mask the pain, enabling patients to
prematurely mobilise and hereby promoting further destruction
of the joint (Brandt 2001)
O B J E C T I V E S
To determine the benefits and harms of intra-articular corticos-
teroids compared with sham or no intervention in people with
knee osteoarthritis in terms of pain, physical function, quality of
life, and safety.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised or quasi-randomised controlled trials with a control
group receiving sham or no intervention.
Types of participants
At least 75% of participants with clinically or radiologically con-
firmed osteoarthritis of the knee. We did not consider trials that
included exclusively people with inflammatory arthritis, such as
rheumatoid arthritis.
Types of interventions
The experimental intervention of interest is any type of intra-
articular corticosteroid. The control interventions of interest are
sham intra-articular corticosteroid and no intervention.
Types of outcome measures
Primary outcomes
The main outcomes were pain and function, as currently recom-
mended for osteoarthritis trials (Altman 1996; Pham 2004), re-
ported within four and six weeks after end of treatment. If data
on more than one pain scale were provided for a trial, we referred
to a previously described hierarchy of pain-related outcomes (Jüni
2006; Reichenbach 2007), and extracted data on the pain scale
that was highest on this list:
1. global pain;
2. pain on walking;
3. Western Ontario and McMaster Universities Arthritis Index
(WOMAC) osteoarthritis index pain subscore;
4. composite pain scores other than WOMAC;
5. pain on activities other than walking;
6. rest pain or pain during the night;
7. WOMAC global algofunctional score;
8. Lequesne osteoarthritis index global score;
9. other algofunctional scale;
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10. participant’s global assessment;
11. physician’s global assessment.
If data on more than one function scale were provided for a trial,
we extracted data according to the hierarchy:
1. global disability score;
2. walking disability;
3. WOMAC disability subscore;
4. composite disability scores other than WOMAC;
5. disability other than walking;
6. WOMAC global scale;
7. Lequesne osteoarthritis index global score;
8. other algofunctional scale;
9. participant’s global assessment;
10. physician’s global assessment
Secondary outcomes
Secondary outcomes were pain and function assessed at 1 to 2,
4 to 6, 13, and 26 weeks after end of treatment, quality of life
assessed at 1 to 2, 4 to 6, 13, and 26 weeks, and the following safety
outcomes: joint space narrowing assessed at 1 to 2, 4 to 6, 13,
and 26 weeks; the number of participants who experienced any
adverse event; withdrewbecause of adverse events; and experienced
any serious adverse events. We defined serious adverse events as
events resulting in hospitalisation, prolongation of hospitalisation,
persistent or significant disability, congenital abnormality or birth
defect of offspring, life-threatening events, or death.
Search methods for identification of studies
Electronic searches
Please see Bellamy 2006 for information on electronic searches
applied in the previous version of this review. Here, we devel-
oped a new search strategy using the electronic databases the
Cochrane Central Register of Controlled Trials (CENTRAL, Is-
sue 1, 2015; mrw.interscience.wiley.com/cochrane/),MEDLINE,
and EMBASE (Ovid SP platform). We did a top-up search in
PubMed to capture citations not yet indexed in MEDLINE. We
used a combination of text words and controlled terms (MeSH
or MeSH-like terms), including truncated variations of prepara-
tion names and brand names combined with terms related to os-
teoarthritis. We applied a validated methodological filter for con-
trolled clinical trials (Dickersin 1994; Lefebvre 2008).Wehave dis-
played the specific search algorithms in Appendix 1 and Appendix
2. We performed the searches from inception to 3 February 2015.
Searching other resources
We manually searched the proceedings of the European League
Against Rheumatism at http://www.abstracts2view.com/eular/
sessionindex.php, the American College of Rheumatology at
http://acrannualmeeting.org/abstracts/abstract-archives/ (we no
longer have access to Osteoarthritis Research Society Interna-
tional); used Science Citation Index to retrieve reports citing rele-
vant articles; contacted content experts and trialists; and screened
reference lists of all obtained articles. We also retrieved and
screened systematic reviews published since January 2004 that
evaluated the effects and safety of corticosteroid injections for knee
osteoarthritis (Abdulla 2013; Arroll 2004; Avouac 2010; Bannuru
2015; Bellamy 2006; Bjordal 2007; Cheng 2012; Garg 2014;
Godwin 2004; Hepper 2009; Hirsch 2013; Maricar 2013). Fi-
nally, we searched the following clinical trial registries: ClinicalTri-
als.gov, metaRegister of Controlled Trials (http://www.controlled-
trials.com/), Australian New Zealand Clinical Trials Registry (
http://www.anzctr.org.au/TrialSearch.aspx), and UMIN Clinical
Trials Registry (http://www.umin.ac.jp/ctr)) to identify ongoing
trials. We performed the last update of the search on 26 March
2015.
Data collection and analysis
We used a generic protocol with instructions for data extraction,
quality assessment, and statistical analyses, which we also used in
our previous Cochrane reviews (da Costa 2012; da Costa 2014;
Reichenbach 2010; Rutjes 2009; Rutjes 2009a; Rutjes 2010).
Selection of studies
Please see Bellamy2006 for information on the selection of studies
in the original review. In this review update, two out of three
review authors independently evaluated all titles and abstracts for
eligibility (MGS, MdN and AR). We resolved disagreements by
discussion.We applied no language restrictions. Ifmultiple reports
described the same trial, we considered all.
Data extraction and management
Please see Bellamy 2006 for information on data extraction and
management in the original review. In this review update, two out
of three review authors (BDC, RF, RH) extracted trial informa-
tion independently and in duplicate using a standardised, piloted
extraction form accompanied by a codebook. We resolved dis-
agreements by discussion. We extracted characteristics of the ex-
perimental intervention (ultrasound-guided injection, use of local
anesthetic, crystalline preparation, and prednisolone equivalance),
the type of control used, dosage, frequency, duration of treatment,
participant characteristics, types of measures used and pain-, func-
tion-, and quality of life-related outcomes, trial design, trial size,
duration of follow-up, type and source of financial support, and
publication status. When necessary, we approximated means and
measures of dispersion from figures in the reports. For cross-over
trials, we extracted data from the first period only. Whenever pos-
sible, we used results from an intention-to-treat analysis.
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Assessment of risk of bias in included studies
Two out of three review authors (BDC, RF, RH) assessed ran-
domisation, blinding, and adequacy of analyses independently and
in duplicate (Jüni 2001). We resolved disagreements by consen-
sus. We assessed two components of randomisation: generation
of allocation sequences and concealment of allocation. We con-
sidered generation of sequences to be adequate if it resulted in
an unpredictable allocation schedule; mechanisms considered ad-
equate included random-number tables, computer-generated ran-
dom numbers, minimisation, coin tossing, shuffling cards, and
drawing lots. We considered trials using an unpredictable alloca-
tion sequence to be randomised and trials using potentially pre-
dictable allocation mechanisms, such as alternation or the allo-
cation of participants according to date of birth to be quasi-ran-
domised. We considered concealment of allocation to be adequate
if participants and investigators responsible for participant selec-
tion were unable to suspect before allocation which treatment
was next.Methods considered adequate included central randomi-
sation; pharmacy-controlled randomisation using identical, pre-
numbered containers; and sequentially numbered, sealed, opaque
envelopes. We considered blinding of participants to be adequate
if a sham injection was used with a syringe that was identical in
appearance to the control intervention, or an attempt was made to
hide the participant’s view of the injected knee by placing screens,
for example. We considered blinding of therapists to be adequate
if a credible blinding attempt was described, such as the use of
independently prepared, opaque syringes. We considered analyses
to be performed according to the intention-to-treat principle if all
randomised participants were included in the analysis. We further
assessed the reporting of primary outcomes, sample size calcula-
tions, and funding source. Finally, we used GRADE to describe
the quality of the overall body of evidence (Guyatt 2008; Higgins
2011), defined as the extent of confidence into the estimates of
treatment benefits and harms.
Measures of treatment effect
We summarised continuous outcomes using standardised mean
differences (SMD) with 95% confidence intervals (CI), with the
differences in mean change from baseline values across treatment
groups divided by the pooled standard deviation (SD). If differ-
ences in mean change were unavailable, we used differences in
mean values at the end of the treatment (da Costa 2013). If some
of the required data were unavailable, we used approximations, as
previously described (Reichenbach 2007). An SMD of -0.20 SD
units can be considered a small difference between the experimen-
tal and control groups, an SMD of -0.50 a moderate difference,
and -0.80 a large difference (Cohen 1988; Jüni 2006). SMDs can
also be interpreted in terms of the percent of overlap of the experi-
mental group’s scores with scores of the control group. An SMDof
-0.20 indicates an overlap in the distribution of pain or function
scores in about 85% of cases, an SMD of -0.50 in about 67%, and
an SMD of -0.80 in about 53% of cases (Cohen 1988; Jüni 2006).
On the basis of a median pooled SD of 2.5 cm, found in large-
scale osteoarthritis trials that assessed pain using a 10-cm visual
analogue scale (VAS) (Nüesch 2009), SMDs of -0.20 correspond
to approximate differences in pain scores between experimental
and control groups of 0.5 cm on a 10-cm VAS, -0.50 of 1.25 cm,
and -0.80 of 2 cm. We back transformed SMDs for function to
a standardised WOMAC disability score (Bellamy 1995), ranging
from 0 to 10 on the basis of a median pooled SD of 2.1 units
observed in large-scale osteoarthritis trials (Nüesch 2009). We ex-
pressed binary outcomes as risk ratios (RR) with 95% CI.
Data synthesis
We used a standard inverse-variance random-effects meta-analysis
to combine the trials (DerSimonian 1986). We quantified hetero-
geneity between trials using the I2 statistic (Higgins 2003), which
describes the percentage of variation across trials that is attributable
to heterogeneity rather than to chance. I2 values of 25% may be
interpreted as low, 50% as moderate, and 75% as high between-
trial heterogeneity (da Costa 2014a), although interpretation of
I2 depends on the size and number of trials included (Rucker
2008). Each trial contributed once to our main effectiveness anal-
yses with the effect estimate closer to our primary time point of in-
terest at four to six weeks.We investigated the association between
trial size and treatment effects in contour-enhanced funnel plots
(Peters 2008), plotting effect sizes on the vertical axis against their
standard errors on the horizontal axis (Sterne 2001; Sterne 2011;
Thompson 1999), accompanied by a regression test for asymme-
try (Egger 1997).We then performed stratified analyses of the pri-
mary outcomes, pain and function, accompanied by interaction
tests according to the following trial characteristics: concealment
of allocation (adequate versus inadequate or unclear), blinding of
participants (adequate versus inadequate or unclear), blinding of
therapists (adequate versus inadequate or unclear), type of control
(placebo versus no intervention), analysis in accordance with the
intention-to-treat principle (yes versus no or unclear), trial size,
funding (funding independent of industry versus industry or un-
clear source of funding), publication type (full journal article ver-
sus other type or unpublished material), ultrasound-guidance of
injections (yes versus no or unclear), use of local anaesthetic (yes
versus no or unclear), use of crystalline preparation (yes versus
no or unclear), prednisolone equivalence dose (≥ 50 mg versus
< 50 mg), use of intra-articular viscosupplementation as co-inter-
vention (yes versus no or unclear), and use of joint lavage as co-
intervention (yes versus no or unclear). We prespecified a cutoff
of 100 allocated participants per trial arm to distinguish between
small and large trials. A sample size of 2 x 100 participants will
yield more than 80% power to detect a small to moderate SMD
of -0.40 at a two-sided P value of 0.05, which corresponds to a
difference of 1 cm on a 10-cm VAS between the experimental and
control intervention (Nüesch 2010). Since only one large trial was
available, we also used a less stringent cutoff of 50 participants
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per arm as previously described (Nüesch 2013). Two arms with
50 participants each will yield more than 80% power to detect
a moderate to large SMD of -0.60. We calculated prednisolone
equivalence doses, with prednisolone 10mg considered equivalent
to betametasone 1.6 mg, cortivazol 0.8 mg, dexamethasone 1.6
mg, hydrocortisone 40 mg, methylprednisolone 8 mg, and triam-
cinolone 8 mg. Interaction tests were based on z scores of the dif-
ference in effect sizes between strata divided by the corresponding
standard error.
We converted SMDs of pain intensity and function to number
needed to treat for an additional beneficial outcome on pain or
function as compared with placebo (NNTB), and number needed
to treat for an additional harmful outcome (NNTH) (da Costa
2012a). We defined treatment response as a 50% improvement
in scores (Clegg 2006; Dworkin 2008; Dworkin 2009). With a
median standardised pain intensity at baseline of 2.4 SD units,
observed in large osteoarthritis trials (Nüesch 2009), this corre-
sponds to a mean decrease in scores of 1.2 SD units. Based on
the median standardised decrease in pain scores of 0.72 SD units
(Nüesch 2009), we calculated that amedian of 31%of participants
in the placebo group would achieve an improvement of pain scores
of 50% or more. We used this percentage as the control group
response rate to calculate NNTBs for pain. Based on the median
standardised WOMAC function score at baseline of 2.7 SD units
and the median standardised decrease in function scores of 0.58
SDunits (Nüesch 2009), 26%of participants in the placebo group
would achieve a reduction in function of 50% or more. Again, we
used this percentage as the control group response rate to calculate
NNTBs for function. We used the median risks of 150 patients
with adverse events per 1000 patient-years, four patients with se-
rious adverse events per 1000 patient-years, and 17 dropouts due
to adverse events per 1000 patient-years as observed in placebo
groups in large osteoarthritis trials to calculate NNTHs for safety
outcomes (Nüesch 2009). All P values were two-sided. We per-
formed analyses using Review Manager 5.3 (RevMan 2014), and
STATA version 14.0 (StataCorp, College Station, Texas).
R E S U L T S
Description of studies
Results of the search
We identified 2324 potentially relevant references through our
electronic searches and 20 additional references through other
sources (Figure 1). We excluded 1769 references after screening ti-
tles and abstracts and retrieved 154 potentially relevant references
for full-text assessment. We included 33 reports on 27 RCTs in
the review.
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Figure 1. Study flow chart. *records with the exact same bibliographic information of another already-
screened record.
Included studies
Twenty-six trials reported effectiveness data. We included all 26
trials in the analysis of pain outcomes, 15 trials in the analysis
of function outcomes (Beyaz 2012; Campos 2013; Castro 2007;
Chao 2010;Di Sante 2012;Gaffney 1995;Henriksen 2015; Lyons
2005; Petrella 2015; Popov 1989; Ravaud 1999; Raynauld 2003;
Smith 2003; Yavuz 2012; Young 2001), and two trials in the anal-
ysis of quality-of-life outcomes (Gaffney 1995; Henriksen 2015).
Of the 26 included trials, 19 compared corticosteroid injection to
sham injection (Beyaz 2012; Cederlof 1966; Chao 2010; Dieppe
1980; Friedman 1980; Gaffney 1995; Henriksen 2015; Jones
1996; NCT00414427; Lyons 2005; Miller 1958; Popov 1989;
Ravaud 1999; Raynauld 2003; Schue 2011; Smith 2003; Yavuz
2012; Young 2001; Zhilyayev 2012), and 7 compared corticos-
teroid injection to no treatment (Campos 2013; Castro 2007; Di
Sante 2012; Fri as 2004; Grecomoro 1992; Ozturk 2006; Petrella
2015).
Triamcinolone was used in 15 trials (Beyaz 2012; Campos 2013;
Castro 2007; Chao 2010; Dieppe 1980; Fri as 2004; Friedman
11Intra-articular corticosteroid for knee osteoarthritis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1980; Gaffney 1995; NCT00414427; Ozturk 2006; Petrella
2015; Popov 1989; Raynauld 2003; Yavuz 2012; Zhilyayev 2012),
methylprednisolone in seven trials (Di Sante 2012; Henriksen
2015; Lyons 2005; Schue 2011; Smith 2003; Yavuz 2012; Young
2001), hydrocortisone in two trials (Miller 1958; Popov 1989),
prednisolone in two trials (Cederlof 1966; Jones 1996), dexam-
ethasonephosphate in one trial (Grecomoro 1992), betametazone
disodium phosphate in one trial (Yavuz 2012), and cortivazol in
one trial (Ravaud 1999). Four trials used viscosupplementation as a
concomitant treatment (Campos 2013; Grecomoro 1992; Ozturk
2006; Petrella 2015), and four trials used lavage as a concomi-
tant treatment (Castro 2007; Fri as 2004; Ravaud 1999; Smith
2003). Two trials used ultrasound to assure intra-articular delivery
of corticosteroid preparation (Di Sante 2012; Henriksen 2015).
The median prednisolone equivalence dose across all trials was 50
mg, and the median number of corticosteroid injections was one.
Trials randomised a median of 76 participants (range 16 to 205
participants).
One additional trial investigating hydrocortisone only reported
safety data, on number of participants experiencing any adverse
event (Wright 1960).
Excluded studies
The Characteristics of excluded studies table displays the reasons
for excluding trials in this systematic review. Typical reasons were
wrong study design, use of active control interventions, more than
25%of participants with rheumatoid arthritis in the sample, or the
use of cross-over designs without providing sufficient information
on the first phase.
Risk of bias in included studies
Figure 2 summarises the methodological characteristics and
sources of funding of included trials. Two trials (7%) reported both
adequate sequence generation and adequate allocation conceal-
ment (Henriksen 2015; Smith 2003), and six trials reported only
adequate sequence generation (Campos 2013; Cederlof 1966; Di
Sante 2012; Ozturk 2006; Petrella 2015; Raynauld 2003). In the
remaining 18 trials, low quality of reporting hampered any judge-
ment regarding sequence generation and concealment of alloca-
tion. Six trials reported the use of indistinguishable interventions
to blind participants, and three trials reported the use of indis-
tinguishable interventions to blind therapists. Nine and five trials
conducted analysis of pain and function outcomes according to
the intention-to-treat principle, respectively. Eleven trials received
financial support from a nonprofit organisation, and no trial was
explicitly supported by a commercial organisation. Twenty-three
trials used parallel-group randomisation, and two were cross-over
trials (Dieppe 1980; Jones 1996).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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For the effectiveness outcomes pain and function, we classified
the quality of the evidence as low in view of the high risk of bias
in the included trials and the high heterogeneity between trials
(Summary of findings for the main comparison) (Guyatt 2008).
For adverse event, dropouts due to adverse events, and serious
adverse event outcomes, we classified the quality of the evidence as
low because of the small number of trials reporting the outcomes
and the small number of overall events, which resulted in imprecise
estimates, and because we considered 50% or more of these trials
to be at high risk of bias (Summary of findings for the main
comparison) (Guyatt 2008).
Effects of interventions
See: Summary of findings for the main comparison
Primary outcomes
Knee pain
Figure 3 presents results of the overall analysis of knee pain re-
ported closest to four to six weeks after end of treatment. Corti-
costeroids were more effective in pain reduction than control in-
terventions (SMD -0.40, 95% CI -0.58 to -0.22), which corre-
sponds to a difference in pain scores of 1.0 cm on a 10-cm VAS
between corticosteroids and sham injection. This corresponds to
a difference in improvement of 17% (95% CI 10% to 25%) be-
tween corticosteroids and sham injection (Summary of findings
for the main comparison), which translates into a NNTB to cause
one additional treatment response on pain of 8 (95% CI 6 to 13)
(Summary of findings for the main comparison). An I2 statistic of
68% indicated a moderate to large degree of between-trial hetero-
geneity (P for heterogeneity < 0.001). A visual inspection of the
funnel plot suggested some asymmetry (asymmetry coefficient -
1.21, 95%CI -3.58 to 1.17), but the corresponding regression test
for asymmetry indicated no evidence for asymmetry (P = 0.30)
(Figure 4).
Figure 3. Forest plot of comparison: 1 Pain, outcome: 1.1 Pain - Main.
14Intra-articular corticosteroid for knee osteoarthritis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 4. Contour-enhanced funnel plot for effects on knee pain. Numbers on x axis refer to standardised
mean differences (SMDs), on y axis to standard errors of SMDs
Figure 5 presents results stratified according to length of follow-
up. Benefits were moderate at 1 to 2 weeks after end of treatment
(SMD -0.48, 95% CI -0.70 to -0.27), small to moderate at 4 to
6 weeks (SMD -0.41, 95% CI -0.61 to -0.21), small at 13 weeks
(SMD -0.22, 95% CI -0.44 to 0.00), and no effect at 26 weeks
(SMD -0.07, 95% CI -0.25 to 0.11). An I2 statistic of ≥ 63%
indicated amoderate to large degree of between-trial heterogeneity
up to 13 weeks after end of treatment (P for heterogeneity ≤
0.001), and an I2 of 0% indicated low heterogeneity at 26 weeks
(P = 0.43).
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Figure 5. Forest plot of comparison: 1 Pain, outcome: 1.2 Pain - Time points. P for trend = 0.001
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Table 1 presents the results of stratified analyses. We found little
or no evidence for an association of SMDs with corticosteroid
dosages, ultrasound guidance, local anesthetic, crystalline prepa-
ration, type of control intervention, financial support, publication
type, concealment of allocation, adequate blinding of participants
or therapists, or intention-to-treat analysis (P ≥ 0.10). There was
some evidence of lower treatment effects in trials that randomised
on average at least 50 participants per group (P = 0.05), or in trials
that used viscosupplementation as a co-intervention (P = 0.08).
There was strong evidence of lower treatment effects in trials that
randomised on average at least 100 participants per group (P =
0.013), or in trials that used joint lavage as a co-intervention (P≤
0.001).
Knee function
Figure 6 presents results of the overall analysis of knee function
reported closest to four to six weeks after end of treatment. Corti-
costeroids were more effective in function improvement than con-
trol interventions (SMD -0.33, 95% CI -0.56 to -0.09), which
corresponds to a difference in functions scores of -0.7 units on
standardised WOMAC disability scale ranging from 0 to 10. This
corresponds to a difference in improvement of 13% (95% CI 4%
to 22%) between corticosteroids and sham injection (Summary of
findings for the main comparison), which translates into a NNTB
to cause one additional treatment response on function of 10 (95%
CI 7 to 33) (Summary of findings for the main comparison). An I
2 statistic of 69% indicated a moderate to large degree of between-
trial heterogeneity (P for heterogeneity < 0.001). A visual inspec-
tion of the funnel plot suggested asymmetry (asymmetry coeffi-
cient -4.07, 95% CI -8.08 to -0.05), and the test for asymmetry
showed evidence for asymmetry (P = 0.047) (Figure 7).
Figure 6. Forest plot of comparison: 2 Function, outcome: 2.1 Function - Main.
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Figure 7. Contour-enhanced funnel plot for effects on knee function. Numbers on x axis refer to
standardised mean differences (SMDs), on y axis to standard errors of SMDs
Figure 8 presents results stratified according to length of follow-
up. Benefits were small to moderate at 1 to 2 weeks after end of
treatment (SMD -0.43, 95% CI -0.72 to -0.14), small at 4 to 6
weeks (SMD -0.36, 95% CI -0.63 to -0.09), no effect at 13 weeks
(SMD -0.13, 95% CI -0.37 to 0.10), and no effect at 26 weeks
(SMD 0.06, 95% CI -0.16 to 0.28). An I2 statistic of ≥ 62%
indicated amoderate to large degree of between-trial heterogeneity
up to 13 weeks after end of treatment (P for heterogeneity ≤
0.004), and an I2 of 0% indicated low heterogeneity at 26 weeks
(P = 0.52).
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Figure 8. Forest plot of comparison: 2 Function, outcome: 2.2 Function - Time points. P for trend = 0.011
Table 2 presents the results of stratified analyses. We found little
or no evidence for an association of SMDs with corticosteroid
dosages, ultrasound guidance, local anaesthetic, crystalline prepa-
ration, joint lavage as a co-intervention, financial support, conceal-
ment of allocation, adequate blinding of participants or therapists,
or intention-to-treat analysis (P≥ 0.10). There was some evidence
of lower treatment effects in trials that randomised on average at
least 50 participants per group (P = 0.023), in unpublished trials
(P = 0.023), in trials that used no intervention as control (P =
0.031), or in trials that used intra-articular viscosupplementation
as a co-intervention (P = 0.06).
Secondary outcomes
Figure 9 presents results of the overall analysis on quality of life
reported closest to four to six weeks after end of treatment. Cor-
ticosteroids had no effect on quality of life compared to control
interventions (SMD -0.01, 95% CI -0.30 to 0.28). An I2 statistic
of 0% indicated a low degree of between-trial heterogeneity (P
for heterogeneity = 0.96). Figure 10 presents results of the overall
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analysis on joint space narrowing reported closest to four to six
weeks after end of treatment. Corticosteroids had no effect in joint
space narowing compared to control interventions (SMD -0.02,
95% CI -0.49 to 0.46). An I2 statistic was not estimable because
only one trial was included in this analysis. There was not enough
data to report results according to the pre-specified time points
neither for quality of life nor joint space narrowing outcomes.
Figure 9. Forest plot of comparison: 3 Quality of life, outcome: 3.1 Quality of life - Main.
Figure 10. Forest plot of comparison: 7 Joint space narrowing, outcome: 7.1 Joint space narrowing - Main.
Figure 11 presents results of the overall analysis on number of
participants experiencing any type of adverse event.We included 2
trials with a total of 84 participants and 46 events in this analysis.
Participants on corticosteroids were 11% less likely to experience
adverse events, but confidence intervals included the null effect
(RR 0.89, 95% CI 0.64 to 1.23). An I2 statistic of 0% indicated
a low degree of between-trial heterogeneity (P for heterogeneity
= 0.44). Due to the imprecision in results, we were not able to
calculate meaningful NNTHs.
Figure 11. Forest plot of comparison: 4 Number of participants experiencing any adverse event, outcome:
4.1 Number of participants experiencing any adverse event - Main.
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Figure 12 presents results of the overall analysis on number of par-
ticipants who withdraw because of adverse events. We included 2
trials with a total of 204 participants and 5 events in this analysis.
Participants on corticosteroids were 67% less likely to withdraw
because of adverse events, but confidence intervals were wide and
included the null effect (RR 0.33, 95% CI 0.05 to 2.07). An I2
statistic of 0% indicated a low degree of between-trial heterogene-
ity (P for heterogeneity = 1.00). Due to the imprecision in results,
we were not able to calculate meaningful NNTHs.
Figure 12. Forest plot of comparison: 5 Number of participants who withdraw because of adverse events,
outcome: 5.1 Number of participants who withdraw because of adverse events -Main.
Figure 13 presents results of the overall analysis on number of
participants experiencing serious adverse events. We included 5
trials with a total of 331 participants and 8 events in this analysis.
Participants on corticosteroids were 27% less likely to withdraw
because of adverse events, but confidence intervals were wide and
included the null effect (RR 0.63, 95% CI 0.15 to 2.67). An I2
statistic of 0% indicated a low degree of between-trial heterogene-
ity (P for heterogeneity = 0.46). Due to the imprecision in results,
we were not able to calculate meaningful NNTHs.
Figure 13. Forest plot of comparison: 6 Number of participants experiencing any serious adverse event,
outcome: 6.1 Number of participants experiencing any serious adverse event - Main.
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Quality of the evidence (GRADE)
We graded the quality of the evidence as ’low’ for all outcomes
because treatment effect estimates were inconsistent with great
variation across trials, pooled estimates were imprecise and did not
rule out relevant or irrelevant clinical effects, and because most
trials had a high or unclear risk of bias.
D I S C U S S I O N
Summary of main results
In this update of the systematic review and meta-analysis by Bel-
lamy (Bellamy 2006), we found most of the identified trials that
compared intra-articular corticosteroids with sham or non-inter-
vention control to be small and hampered by low methodologi-
cal quality, and graded the quality of evidence for the major out-
comes as ’low’. Only one trial was considered large according to
our prespecified criteria (Fri as 2004), with an average sample size
of 100 participants or more per group, but this trial did not report
adequate randomisation, participant blinding, or an intention-to-
treat analysis. Conversely, only one trial reported adequate ran-
domisation, participant blinding, and an intention-to-treat analy-
sis (Henriksen 2015), but it was of moderate size only. An analysis
of multiple time points suggested that effects decrease over time
(P ≤ 0.011), and our analysis provides no evidence that an effect
remains six months after a corticosteroid injection. Whether there
are clinically important benefits after one to six weeks remains
unclear in view of the overall quality of the evidence. A single
trial included in this review described adequate measures to con-
sistently minimise biases (Henriksen 2015); this trial did not find
any benefit of intra-articular corticosteroids (SMD 0.04, 95% CI
-0.43 to 0.35).
Quality of the evidence
The overall analyses of pain and function were difficult to inter-
pret in view of the large extent of heterogeneity between trials.
Stratified analyses suggested an association of estimates of treat-
ment effects with sample size (P ≤ 0.05), and funnel plots ap-
peared asymmetrical, even though the accompanying asymmetry
test was positive only for function (P = 0.047). Stratified analy-
ses according to components of methodological quality showed
negative interaction tests. Conversely, trials with protocol-man-
dated concomitant lavage or viscosupplementation treatment in
both experimental and control groups appeared to show smaller
benefits of corticosteroids as compared with control.
The largest trial used joint lavage as concomitant treatment in all
participants (Fri as 2004). It therefore ultimately remains unclear
whether the lack of treatment effect in this trial is a function of
study size in the presence of small-study effects (Nüesch 2010), or
a function of the concomitant use of joint lavage, which may act as
an effect modifier even in the absence of a specific therapeutic ef-
fect (Reichenbach 2010). However, among the three largest trials,
which included at least 50 participants per group, only one used
lavage (Fri as 2004), another used viscosupplementation as con-
comitant treatment (Campos 2013), and the third used neither
(Henriksen 2015). When pooling these moderate-to-large trials,
we found only a small, clinically irrelevant, and statistically non-
significant effect on pain and function with a low degree of het-
erogeneity.
For other clinical characteristics including the use of ultrasound to
guide injections, crystalline preparations, and prednisone equiva-
lent doses, we did not find a treatment by subgroup interaction.
Only two trials used ultrasound guidance to ensure proper place-
ment of needles (Di Sante 2012, Henriksen 2015), however con-
tradictory results and insufficient data are available to determine
whether ultrasound guidance is associated with larger treatment
effects.
Potential biases in the review process
We based our review on an extensive literature search, and so it
seems unlikely that we missed relevant trials, provided that they
were published as full-text articles or accessible in conference pro-
ceedings or trial registries (Egger 2003). Two review authors inde-
pendently performed selection of trials and data extraction in or-
der to reduce bias and transcription errors (Egger 2001; Gøtzsche
2007). We are therefore confident that potential biases during the
review process were minimised.
Agreements and disagreements with other
studies or reviews
Our update of the previous systematic review and meta-analysis
by Bellamy identified 14 new trials that compared intra-articular
corticosteroids with sham or non-intervention control (Bellamy
2006). In view of the overall body of evidence, we are as confident
as Bellamy et al that no effect of intra-articular corticosteroids re-
mains after six months, but are less confident than Bellamy that
there is a clinically relevant short-term effect in view of large het-
erogeneity and possible small-study effects.
The most recent systematic review and network meta-analysis
on intra-articular corticosteroids in knee osteoarthritis (Bannuru
2015), carried out in August 2014, identified seven trials com-
paring intra-articular corticosteroids to intra-articular placebo, all
of which we included in our analysis. Again, we are less confi-
dent than these authors that there is a clinically relevant short-
term effect of intra-articular corticosteroids considering the issues
described above.
22Intra-articular corticosteroid for knee osteoarthritis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
It remains unclear whether there are clinically important benefits
one to six weeks after corticosteroid injection in view of the low
quality of the included trials, the large amount of heterogeneity,
and the likely presence of small-study effects (Nüesch 2010). In-
tra-articular corticosteroids should therefore be considered exper-
imental in knee osteoarthritis and not be routinely used until ad-
equately powered and properly designed trials clearly indicate a
short- to mid-term benefit.
Implications for research
An adequately designed, multicentre, randomised, double-blind,
sham-controlled, parallel-group trial is required to confirm or re-
fute clinically relevant short- to mid-term benefits of intra-articu-
lar corticosteroids in knee osteoarthritis. A sample size of 100 par-
ticipants per group would yield 80% power to detect a clinically
meaningful moderate effect size of 0.4 standard deviation units in
terms of pain reduction. The trial should use ultrasound guidance
to ensure intra-articular needle placement as recently described by
Henriksen et al (Henriksen 2015).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Beyaz 2012
Methods Randomised controlled trial
3-arm parallel-group design
Trial duration: 12 weeks
Participants 82 participants with knee osteoarthritis were randomised
73 participants were reported at baseline
Number of females: 59 of 73 (81%)
Mean age: 69.1 years
Interventions Experimental intervention
40 mg triamcinolone acetonide (1 ml) plus 20 mg bupivacaine (4 ml), single intra-
articular injection
Control intervention
1 ml saline plus 20 mg bupivacaine (4 ml), single intra-articular injection
Outcomes Extracted pain outcome: WOMAC pain
Extracted function outcome: WOMAC function
Maximum follow-up: 12 weeks
Notes Funding: Boztepe State Hospital, Ordu, Republic of Turkey
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomized by
the closed-envelope technique into three
groups”. Because the “closed-envelope
technique” was not further specified, the
risk of selection bias was considered unclear
Allocation concealment (selection bias) Unclear risk Quote: “Patients were randomized by
the closed-envelope technique into three
groups”. Because the “closed-envelope
technique” was not further specified, the
risk of selection bias was considered unclear
Blinding of participants? Low risk Quote: “Since the solutions were in differ-
ent colors, sticker was used to cover injec-
tors to hide to ensure blinding.”
Blinding of health care provider(s) Low risk Quote: “Injections were administered by
another blinded investigator.”
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Beyaz 2012 (Continued)
Intention-to-treat analysis performed? Pain High risk 9 out of 82 participants were excluded be-
cause (quote) “they did not come for fol-
low-up”
Intention-to-treat analysis performed?
Function
High risk 9 out of 82 participants were excluded be-
cause (quote) “they did not come for fol-
low-up”
Campos 2013
Methods Randomised controlled trial
2-arm parallel-group design
Trial duration: 24 weeks
Participants 104 participants with knee osteoarthritis were randomised
104 participants were reported at baseline
Number of females: 79 out of 104 (76%)
Mean age: 63.0 years
Interventions Experimental intervention
20 mg triamcinolone hexacetonide (1 ml) plus 6 ml hylan GF-20, single intra-articular
injection
Control intervention
6 ml hylan GF-20 intra-articularly, single intra-articular injection
Quote: “Patients with bilateral disease had both knees treated with the same drug, but
only one knee (reported by the patient as the worst) was included in the study”
Outcomes Extracted pain outcome: WOMAC Pain
Extracted function outcome: WOMAC Global
Maximum follow-up: 24 weeks
Notes Funding: São Paulo Research Foundation (FAPESP) (Sao Paulo, Brazil)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed by
a computer-generated program (available
at: http://www.randomization.com/).”
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Blinding of participants? Low risk Quote: “Patients were blinded (blocked
fromwatching the procedures by the use of
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Campos 2013 (Continued)
a windscreen sunshade and did not know
to which group they were assigned).”
Blinding of health care provider(s) Unclear risk Physicians were not explicitly described as
blinded, so the risk of performance bias was
unclear
Intention-to-treat analysis performed? Pain High risk 5 of 52 participants excluded in experimen-
tal group, 6 of 52 participants excluded in
control group
Intention-to-treat analysis performed?
Function
High risk 5 of 52 participants excluded in experimen-
tal group, 6 of 52 participants excluded in
control group
Castro 2007
Methods Randomised controlled trial
5-arm parallel-group design
Trial duration: 12.9 months
Participants 150 participants with knee osteoarthritis were randomised
Unclear number of participants with knee osteoarthritis reported at baseline
Number of females: 115
Mean age: 65.4
Interventions Experimental intervention
Triamcinolone acetonide (no dosage or unit specified) + joint lavage, single intra-articular
application
Control intervention
Joint lavage, single intra-articular application
Outcomes Extracted pain outcome: WOMAC Pain
Extracted function outcome: WOMAC Function
Maximum follow-up: 12.9 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
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Castro 2007 (Continued)
the risk of selection bias was unclear
Blinding of participants? Unclear risk It was unclear if method used to blind par-
ticipants was appropriate
Blinding of health care provider(s) Unclear risk Physicians were not explicitly described as
blinded, so the risk of performance bias was
unclear
Intention-to-treat analysis performed? Pain Low risk All randomised participants included in the
analysis
Intention-to-treat analysis performed?
Function
Low risk All randomised participants included in the
analysis
Cederlof 1966
Methods Randomised controlled trial
2-arm parallel-group design
Trial duration: 8 weeks
Participants 51 injections in 44 knees belonging to 44 participants with knee osteoarthritis were
randomised
Unclear number of participants reported at baseline
Number of females: 41 of 44 (93.2%)
Mean age: Not reported
Interventions Experimental intervention
50 mg prednisolone acetate (2 ml), single intra-articular injection
Control intervention
2 ml physiologic saline, single intra-articular injection
Outcomes Extracted pain outcome: Patient global assessment
Notes Funding: Aktiebolaget Ferrosan, Malmö, Sweden
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The out-patient department nurse
decided which fluid was to be injected by
tossing a coin”
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
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Cederlof 1966 (Continued)
Blinding of participants? Unclear risk It was unclear if method used to blind par-
ticipants was appropriate
Blinding of health care provider(s) Unclear risk Physicians were not explicitly described as
blinded, so the risk of performance bias was
unclear
Intention-to-treat analysis performed? Pain Low risk All randomised participants included in the
analysis
Intention-to-treat analysis performed?
Function
Unclear risk Did not report extractable function out-
come data
Chao 2010
Methods Randomised controlled trial
2-arm parallel-group design
Trial duration: 12 weeks
Participants 79 participants with knee osteoarthritis were randomised
79 participants were reported at baseline
Number of females: 2 of 79 (2.5%)
Mean age: 64.3 years
Interventions Experimental intervention
40 mg triamcinolone acetonide (1 ml), single intra-articular injection
Control intervention
1 ml 0.9% saline, single intra-articular injection
Outcomes Extracted pain outcome: WOMAC Pain
Extracted function outcome: WOMAC Global
Maximum follow-up: 12 weeks
Notes Funding: National Skeletal Muscle Research Center, NIH Grant HD050837
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
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Chao 2010 (Continued)
Blinding of participants? Low risk Quote: “Patients and assessorswere blinded
to treatment status” “Patients were then
randomized to receive an injection of either
(...) triamcinolone acetonide or (...) saline,
which were drawn into a syringe covered
with opaque tape prior to the patient en-
counter.”
Blinding of health care provider(s) High risk Quote: “Injections were given (...) by a
non-blinded physician”
Intention-to-treat analysis performed? Pain High risk 9 of 40 participants excluded in experimen-
tal group, 9 of 39 participants excluded in
control group
Intention-to-treat analysis performed?
Function
High risk 9 of 40 participants excluded in experimen-
tal group, 9 of 39 participants excluded in
control group
Di Sante 2012
Methods Randomised controlled trial
3-arm parallel-group design
Trial duration: 4 weeks
Participants 60 participants with knee osteoarthritis were randomised
60 participants were reported at baseline
Mean age: 70.6
Interventions Experimental interventions
40 mg methylprednisolone acetate and lidocaine hydrochloride, single intra-articular
injection + Horizontal therapy* locally (10 times over 2 weeks, each lasting 30 minutes)
Control intervention
Horizontal therapy* locally (10 times over 2 weeks, each lasting 30 minutes)
Treatment duration: 4 weeks
*Horizontal therapy was described as (quote): “Placement of 4 cutaneous electrodal pads
(8 x 13 cm), one in center of the popliteal, one on the patella and two others at the
posterior proximal site of the thighs, with a stimulation frequency oscillating at 100 Hz
between 4400 and 12346 Hz for 30 minutes”
Maximum follow-up: 4 weeks
Outcomes Extracted pain outcome: Pain overall
Extracted function outcome: WOMAC Function
Maximum follow-up: 4 weeks
Notes
Risk of bias
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Di Sante 2012 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “(...) using a computer generated 1:
1:1 allocation sequence.”
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Blinding of participants? High risk No intra-articular sham injection in the
placebo group (local therapy only)
Blinding of health care provider(s) High risk No intra-articular sham injection in the
placebo group (local therapy only)
Intention-to-treat analysis performed? Pain Low risk All randomised participants included in the
analysis
Intention-to-treat analysis performed?
Function
Low risk All randomised participants included in the
analysis
Dieppe 1980
Methods Randomised controlled trial
2-arm cross-over design
Trial duration: 2 weeks
Participants 24 knees belonging to 16 participants with knee osteoarthritis were randomised
24 knees belonging to 16 participants were reported at baseline
Mean age: 65
Number of females: 13 out of 16 (81%)
Interventions Experimental intervention
20 mg triamcinalone hexacetonide (1 ml), single intra-articular injection
Control intervention
1 ml of saline, single intra-articular injection
Cross-over after 1week. Every participant received 1 injection (experimental and control)
each
Outcomes Extracted pain outcome: Pain overall
Maximum follow-up: 1 week
Notes 2 trials were reported in the same paper. Trial A did not report pain outcomes seperately
for treatment and intervention and was excluded. Trial B was included in the analysis
Risk of bias
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Dieppe 1980 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Blinding of participants? High risk Quote: Described as “single-blind, blind-
observer”, implying that participants were
not blinded
Blinding of health care provider(s) High risk Quote: Described
as “single-blind, blind-observer”, implying
that healthcare providers were not blinded
Intention-to-treat analysis performed? Pain Low risk All randomised participants included in the
analysis
Intention-to-treat analysis performed?
Function
Unclear risk Not applicable, no function outcome re-
ported
Friedman 1980
Methods Randomised controlled trial
2-arm parallel-group design
Trial duration: 8 weeks
Participants 34 participants with knee osteoarthritis were randomised
34 participants were reported at baseline
Number of females: Not reported
Mean age: 60.0 years
Interventions Experimental intervention
20 mg triamcinolone hexacetonide, single intra-articular injection
Control intervention
“Polysorbate, sorbitol solution, benzyl alcohol and water”, single intra-articular injection
Outcomes Extracted pain outcome: Pain overall
Maximum follow-up: 8 weeks
Notes Funding: Grant from the Eastern Pennsylvania Chapter of the Arthritis Foundation and
by the Philadelphia Foundation
Risk of bias
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Friedman 1980 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocationwas not clearly reported, so the
risk of selection bias was unclear. Quote:
“Half of the patients, selected according
to a predetermined random schedule, were
treated (...).”
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Blinding of participants? Low risk Quote: “During the time of [the injection]
(...), the physician and patient were posi-
tioned so that neither could see the nurse’s
face nor the material she injected. Thus,
neither had any direct information con-
cerning what was injected and, practically
speaking, had no contact with the only per-
son who knew”
Blinding of health care provider(s) Low risk Quote: “The physician-experimenter per-
formed the arthrocentesis (...) a nurse-assis-
tant entered the room and performed the
injection through the intraarticular needle,
and left the room. During the time of this
taking place, the physician and patient were
positioned so that neither could see the
nurse’s face nor the material she injected.
Thus, neither had any direct information
concerning what was injected and, practi-
cally speaking, hadno contactwith the only
person who knew”
Intention-to-treat analysis performed? Pain Low risk All randomised participants included in the
analysis. Quote: “All patients were seen 1
wk, 4 wk, 6 wk and 8 wk post-injection ex-
cept those whose pain scores at any subse-
quent evaluationwere the same as their pre-
treatment scores; they were not seen fur-
ther. It was assumed that their scores would
no longer improve and they were counted
as remaining at their pre-treatment level
throughout the experiment”
Intention-to-treat analysis performed?
Function
Unclear risk Not applicable, no function outcome re-
ported
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Fri as 2004
Methods Randomised controlled trial
2-arm parallel-group design
Trial duration: 12 weeks
Participants 299 knees belonging to 205 participants with knee osteoarthritis were randomised
299 knees belonging to 205 participants were reported at baseline
Number of females: 234 (78%) of 299 knees belonged to female participants
Mean age: 67.0 years
Interventions Experimental intervention
40mg triamcinolone acetonide plus lavage (3 L of cold (8°C) saline), single intra-articular
application
Control intervention
Lavage (3 L of cold (8°C) saline), single intra-articular application
Outcomes Extracted pain outcome: Pain overall
Maximum follow-up: 12 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Blinding of participants? Unclear risk Although the authors stated “Glucocor-
ticoid treatment with triamcinolone ace-
tonide was always given on a blind basis”,
they also stated that this was an open trial
(Quote: “The study was of the longitudi-
nal, open, prospective, controlled type”).
The risk of performance bias was therefore
considered unclear
Blinding of health care provider(s) Unclear risk Although the authors stated “Glucocor-
ticoid treatment with triamcinolone ace-
tonide was always given on a blind basis”,
they also stated that this was an open trial
(Quote: “The study was of the longitudi-
nal, open, prospective, controlled type”).
The risk of performance bias was therefore
considered unclear
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Fri as 2004 (Continued)
Intention-to-treat analysis performed? Pain High risk 82 of 299 knees were excluded at 1 month,
51 of 299 knees were excluded at 3 months
Intention-to-treat analysis performed?
Function
Unclear risk Not applicable, no function outcome re-
ported
Gaffney 1995
Methods Randomised controlled trial
2-arm parallel-group design
Trial duration: 6 weeks
Participants 84 participants with knee osteoarthritis were randomised
84 participants were reported at baseline
Number of females: 60 out of 84 (71%)
Mean age: 67.0 years
Interventions Experimental intervention
20 mg triamcinolone hexacetonide (1 ml), single intra-articular injection
Control intervention
1 ml of 0.9% normal saline, single intra-articular injection
Outcomes Extracted pain outcome: Pain overall
Extracted function outcome: Other function composite
Maximum follow-up: 6 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Blinding of participants? Low risk Quote: “Although this study was not, by
strict definition, double-blinded, we at-
tempted to ensure that patients were not
aware of the treatment allocated to them,
by shielding the identity of the treatment
received from their view at the time of in-
jection; only the injecting physician (IL)
was aware of the nature of the injection ad-
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Gaffney 1995 (Continued)
ministered.”
Blinding of health care provider(s) High risk Quote: “Although this study was not, by
strict definition, double-blinded, we at-
tempted to ensure that patients were not
aware of the treatment allocated to them,
by shielding the identity of the treatment
received from their view at the time of in-
jection; only the injecting physician (IL)
was aware of the nature of the injection ad-
ministered.”
Intention-to-treat analysis performed? Pain Unclear risk 2 of 42 participants in control group with-
drew. Itwas unclearwhether all participants
randomised were also analysed
Intention-to-treat analysis performed?
Function
Unclear risk 2 of 42 participants in control group with-
drew. Itwas unclearwhether all participants
randomised were also analysed
Grecomoro 1992
Methods Randomised controlled trial
2-arm cross-over design
Trial duration: 8.6 weeks
Participants 40 participants with knee osteoarthritis were randomised
40 participants were reported at baseline
Number of females: 27 out of 40 (67.5%)
Mean age: 42.3 years
Interventions Experimental intervention
0.4 mg dexamethasonephosphate plus 20 mg sodium hyaluronate in 2 ml phosphate
buffer, 5 intra-articular injections, 1 weekly for 5 weeks
Control intervention
20mg sodiumhyaluronate in 2ml phosphate buffer, 5 intra-articular injections, 1weekly
for 5 weeks
Outcomes Extracted pain outcome: Pain on activities other than walking
Maximum follow-up: 8.6 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Grecomoro 1992 (Continued)
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Blinding of participants? High risk Quote: “The trial design was open and ran-
domized.”
Blinding of health care provider(s) High risk Quote: “The trial design was open and ran-
domized.”
Intention-to-treat analysis performed? Pain Low risk All randomised participants included in the
analysis
Intention-to-treat analysis performed?
Function
Unclear risk Not applicable, no function outcome re-
ported
Henriksen 2015
Methods Randomised controlled trial
2-arm parallel-group design
Trial duration: 26 weeks
Participants 100 participants with knee osteoarthritis were randomised
100 participants were reported at baseline
Number of females: 61 out of 100 (61%)
Mean age: 63.4 years
Interventions Experimental intervention
40 mg methylprednisolone acetate (1 ml) dissolved in 4 ml of lidocaine hydrochloride,
single intra-articular injection + 12-week exercise program
Control intervention
1 ml isotonic saline mixed with 4 ml of lidocaine hydrochloride, single intra-articular
injection + 12-week exercise program
Outcomes Extracted pain outcome: Other pain composite
Extracted pain function: Other function composite
Maximum follow-up: 26 weeks
Notes Funding: Grants by: 10-093704 from the Danish Council for Independent Research
Medical Science, Oak Foundation, Association of Danish Physiotherapists, Lundbeck
Foundation, Capital Region of Denmark
Risk of bias
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Henriksen 2015 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A computer-generated random-
ization sequence was produced before any
patients were enrolled that allocated partic-
ipants in permuted blocks of 2 to 6 to the
corticosteroid or the placebo group (1:1).”
Allocation concealment (selection bias) Low risk Quote: “The randomization sequence was
prepared by a biostatistician with no clini-
cal involvement in the trial (R.C.). The al-
location was concealed in a password-pro-
tected computer file only accessible by the
biostatistician. Individual allocations were
held in sealed, opaque, consecutively num-
bered envelopes.”
Blinding of participants? Low risk Quote: “To ensure blinding of the partici-
pants and the clinician performing the in-
jections, the syringes were prepared by the
study nurse in the absence of participants
and blinded study staff. Because the cor-
ticosteroid liquid is milky white and the
saline is clear, the syringes were masked
with opaque tape to prevent disclosure of
the content during the injection procedure.
”
Blinding of health care provider(s) Low risk Quote: “To ensure blinding of the partici-
pants and the clinician performing the in-
jections, the syringes were prepared by the
study nurse in the absence of participants
and blinded study staff. Because the cor-
ticosteroid liquid is milky white and the
saline is clear, the syringes were masked
with opaque tape to prevent disclosure of
the content during the injection procedure.
”
Intention-to-treat analysis performed? Pain Low risk All randomised participants included in the
analysis
Intention-to-treat analysis performed?
Function
Low risk All randomised participants included in the
analysis
45Intra-articular corticosteroid for knee osteoarthritis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Jones 1996
Methods Randomised controlled trial
2-arm cross-over design
Trial duration: 16 weeks
Participants 59 participants with knee osteoarthritis were randomised
59 participants were reported at baseline
Number of females: 37 out of 59 (63%)
Mean age: 70.6 years
Interventions Experimental intervention
40 mg methyl prednisolone acetate (1 ml), single intra-articular injection
Control intervention
1 ml 0.9% saline, single intra-articular injection
Cross-over after 8 weeks. Every participant received 1 injection (experimental and con-
trol) each
Outcomes Extracted pain outcome: Pain on activities other than walking
Maximum follow-up: 8 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Blinding of participants? Unclear risk Quote: “Each injection was given by a sec-
ond operator, thus blinding both patient
and assessor.” No further description of
blinding
Blinding of health care provider(s) Unclear risk Quote: “Each injection was given by a sec-
ond operator, thus blinding both patient
and assessor.” No further description of
blinding
Intention-to-treat analysis performed? Pain High risk Quotes: “As some data was missing due
to patient withdrawal, all analyses were
performed on a last measures carried for-
ward, intention to treat basis”, but still not
all participants randomised were analysed.
Quote: “One patient failed to enter the
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Jones 1996 (Continued)
study and received no injection, leaving 59
patients available for the analysis.”
Intention-to-treat analysis performed?
Function
Unclear risk Not applicable, no function outcome re-
ported
Lyons 2005
Methods Randomised controlled trial
2-arm parallel-group design
Trial duration: 8.6 weeks
Participants 20 participants with knee osteoarthritis were randomised
Unclear number of participants with knee osteoarthritis reported at baseline
Number of females: 11
Mean age: 59.7
Interventions Experimental intervention
80 mg methylprednisolone (2 ml) + 5 ml 1% lignocaine, single intra-articular injection
Control intervention
10 ml of 1% lignocaine, single intra-articular injection
Outcomes Extracted pain outcome: Pain overall
Extracted function outcome: Global disability score
Maximum follow-up: 8.6 weeks
Notes Funding: West London Research Network, Primary Care Scientist Award funded by the
Department of Health
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Blinding of participants? Unclear risk It was unclear if method used to blind
healthcare providers was appropriate
Blinding of health care provider(s) High risk Quote: “(The study) was single blind, with
the principal investigator administering the
treatment and also measuring outcome.”
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Lyons 2005 (Continued)
Intention-to-treat analysis performed? Pain Low risk All randomised participants included in the
analysis
Intention-to-treat analysis performed?
Function
Low risk All randomised participants included in the
analysis
Miller 1958
Methods Randomised controlled trial
5-arm parallel-group design
Trial duration: 33.8 weeks
Participants 202 participants with knee osteoarthritis were randomised
Unclear number of participants reported at baseline
Number of females: 122
Mean age: not reported
Interventions Experimental intervention
50 mg of hydrocortisone (2 ml) + 8 ml of physiological normal saline, 5 intra-articular
injections, interval of 2 weeks
Control intervention
Physiological normal saline solution (no dosage), 5 intra-articular injections, interval of
2 weeks
Outcomes Extracted pain outcome: Patients’ global assessment
Maximum follow-up: 25.8 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Blinding of participants? Unclear risk It was unclear if method used to blind par-
ticipants was appropriate
Blinding of health care provider(s) Unclear risk Physicians were not explicitly described as
blinded, so the risk of performance bias was
unclear
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Miller 1958 (Continued)
Intention-to-treat analysis performed? Pain High risk 21 of 202 participants were excluded
Intention-to-treat analysis performed?
Function
Unclear risk Not applicable, no function outcome re-
ported
NCT00414427
Methods Randomised controlled trial
2-arm parallel-group design
Trial duration: 12 weeks
Participants 79 participants with knee osteoarthritis were randomised
79 participants were reported at baseline
Number of females: 3 out of 79 (4%)
Mean age: 63.0 years
Interventions Experimental intervention
40 mg triamcinolone acetonide, single intra-articular injection
Control intervention
0.9% saline (no dosage), single intra-articular injection
Outcomes Extracted pain outcome: WOMAC Pain
Maximum follow-up: 12 weeks
Notes Funding: University of California, San Diego
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Blinding of participants? Unclear risk It was unclear if method used to blind par-
ticipants was appropriate
Blinding of health care provider(s) Unclear risk It was unclear if method used to blind
healthcare providers was appropriate
Intention-to-treat analysis performed? Pain High risk 7 of 40 participants excluded in experimen-
tal group, 5 of 39 participants excluded in
control group
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NCT00414427 (Continued)
Intention-to-treat analysis performed?
Function
Unclear risk Not applicable, no function outcome re-
ported
Ozturk 2006
Methods Randomised controlled trial
2-arm parallel-group design
Trial duration: 52 weeks
Participants 47 participants with knee osteoarthritis were randomised
40 participants were reported at baseline
Number of females: 39 out of 47 (83%)
Mean age: 58.0 years
Interventions Experimental intervention
40 mg triamcinolone acetonide (1 ml) plus 2 ml sodium hyaluronate. Sodium
hyaluronate was administered in 3 intra-articular injections in the first month and 3
intra-articular injections during the sixth month, triamcinolone acid was added prior to
the first and fourth application
Control intervention
2 ml sodium hyaluronate, 3 intra-articular injections in the first month, and 3 intra-
articular injections during the sixth month
Outcomes Extracted pain outcome: WOMAC Pain
Maximum follow-up: 25.9 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were assigned to one of
the two treatment groups based on a table
of randomly assorted digits: A and B.”
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Blinding of participants? Unclear risk It was unclear if participants were blinded
(trial described as “single blind” but no de-
scription of who was blinded)
Blinding of health care provider(s) Unclear risk It was unclear if healthcare providers were
blinded (trial described as “single blind” but
no description of who was blinded)
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Ozturk 2006 (Continued)
Intention-to-treat analysis performed? Pain High risk 7 of 23 participants excluded in experimen-
tal group, 0 of 24 participants excluded in
control group
Intention-to-treat analysis performed?
Function
Unclear risk Not applicable, no function outcome re-
ported
Petrella 2015
Methods Randomised controlled trial
2-arm parallel-group design
Trial duration: 26 weeks
Participants 98 participants with knee osteoarthritis were randomised
98 participants were reported at baseline
Number of females: 56 out of 98 (57%)
Mean age: 59.7 years
Interventions Experimental intervention
10 mg triamcinolone acetonide + hyaluronan solution (no dosage stated), 6 ml total,
single intra-articular injection
Control intervention
Hyaluronan solution (no dosage stated), single intra-articular injection
Outcomes Extracted pain outcome: WOMAC Pain
Extracted function outcome: WOMAC Function
Maximum follow-up: 26 weeks
Notes Funding: Carbylan Therapeutics
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomization treatment was
computer generated and was stratified by
study center.”
Allocation concealment (selection bias) Unclear risk Quote: “The randomization treatment was
computer generated and was stratified by
study center.”
Blinding of participants? Unclear risk It was unclear if method used to blind par-
ticipants was appropriate
Blinding of health care provider(s) High risk Quote: “An injecting physician delivered
the randomized treatment and remained
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Petrella 2015 (Continued)
unblinded.”
Intention-to-treat analysis performed? Pain High risk 2 of 33 participants excluded in experimen-
tal group, 1 of 33 participants excluded in
control group
Intention-to-treat analysis performed?
Function
High risk 2 of 33 participants excluded in experimen-
tal group, 1 of 33 participants excluded in
control group
Popov 1989
Methods Randomised controlled trial
5-arm parallel-group design
Trial duration: 2.7 weeks
Participants 48 participants with knee osteoarthritis were randomised
Unclear number of participants with knee osteoarthritis reported at baseline
Number of females: 38
Mean age: 55 years
Interventions Experimental interventions
Intervention (A): 40 mg triamcinolone, 3 intra-articular injections, interval 1 week
Intervention (B): 50 mg hydrocortisone, 3 intra-articular injections, interval 1 week
Control intervention
Saline solution (no dosage stated), 2 intra-articular injections, interval 1 week
Outcomes Extracted pain outcome: (A)-(B): other algofunctional
Extracted function outcome: (A)-(B): other algofunctional
Maximum follow-up: 0.7 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Blinding of participants? Unclear risk It was unclear if method used to blind par-
ticipants was appropriate
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Popov 1989 (Continued)
Blinding of health care provider(s) Unclear risk It was unclear if method used to blind
healthcare providers was appropriate
Intention-to-treat analysis performed? Pain Unclear risk It was unclear whether all participants ran-
domised were also analysed
Intention-to-treat analysis performed?
Function
Unclear risk It was unclear whether all participants ran-
domised were also analysed
Ravaud 1999
Methods Randomised controlled trial
2 x 2 factorial design
Trial duration: 24 weeks
Participants 98 participants with knee osteoarthritis were randomised
98 participants were reported at baseline
Number of females: 66 out of 98 (67%)
Mean age: 65.4
Interventions Experimental interventions
Intervention (A): 3.75 mg cortivazol (1.5 ml), single intra-articular injection
Intervention (B): Lavage, single intra-articular application + 3.75 mg cortivazol (1.5 ml)
, single intra-articular injection
Control intervention
Intervention (A): 1.5 ml 0.9% normal saline, single intra-articular injection
Intervention (B): Lavage, single intra-articular application
Outcomes Extracted pain outcome: Pain overall
Extracted function outcome: Lequesne index
Maximum follow-up: 24 weeks
Notes Funding: Société Française de Rhumatologie and theDirection de la RechercheClinique
(Assistance Publique - Hôpitaux de Paris)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
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Ravaud 1999 (Continued)
Blinding of participants? Unclear risk Quote: “The study was double-blind in re-
lation to the IA corticosteroid and open
with regard to joint lavage.”
Blinding of health care provider(s) Unclear risk Quote: “The study was double-blind in re-
lation to the IA corticosteroid and open
with regard to joint lavage. However, the
procedure (joint lavage and/or IA injection)
was performed by a physician other than
the blinded evaluator.”
Intention-to-treat analysis performed? Pain Low risk All randomised participants included in the
analysis. Quote: “The last observation-car-
ried-forward procedure was used to adjust
for missing values.”
Intention-to-treat analysis performed?
Function
Low risk All randomised participants included in the
analysis. Quote: “The last observation-car-
ried-forward procedure was used to adjust
for missing values.”
Raynauld 2003
Methods Randomised controlled trial
2-arm parallel-group design
Trial duration: 54 weeks
Participants 68 participants with knee osteoarthritis were randomised
68 participants were reported at baseline
Number of females: 42 out of 68 (68%)
Mean age: 63.2 years
Interventions Experimental intervention
40 mg triamcinolone acetonide (1 ml), 8 intra-articular injections, interval 3 months,
over 21 months
Control intervention
1 ml saline intra-articularly, 8 intra-articular injections, interval 3 months, over 21
months
Outcomes Extracted pain outcome: WOMAC Pain. After end of treatment (during follow-up)
Extracted function outcome:WOMACFunction. After end of treatment (during follow-
up)
Maximum follow-up: 12.9 weeks
Notes Funding: Fonds de la recherche en santé du Québec
Risk of bias
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Raynauld 2003 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomly assigned
to the IA steroid or IA saline group based
on a table of randomly assorted digits.”
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Blinding of participants? Unclear risk Study described as double-blind but no de-
scription of method of blinding provided
Blinding of health care provider(s) High risk Study described as double-blind. The fol-
lowing statements indicate that “double-
blind” in this trial means that only patients
and outcome assessors were blinded: “In
order to preserve the blind, the injections
were givenby a rheumatologist (DCorBH)
other than the evaluators.” “Investigators
performed these evaluations in a blinded
manner using validated measures.”
Intention-to-treat analysis performed? Pain High risk 1 of 34 participants excluded in experimen-
tal group, 1 of 34 participants excluded in
control group
Intention-to-treat analysis performed?
Function
High risk 1 of 34 participants excluded in experimen-
tal group, 1 of 34 participants excluded in
control group
Schue 2011
Methods Randomised controlled trial
3-arm parallel-group design
Trial duration: 8 weeks
Participants 16 participants with knee osteoarthritis were randomised
Unclear number of participants with knee osteoarthritis reported at baseline
Number of females: not reported
Mean age: not reported
Interventions Experimental intervention
80 mg methylprednisolone, single intra-articular injection
Control intervention
Saline (no dosage specified), single intra-articular injection
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Schue 2011 (Continued)
Outcomes Extracted pain outcome: WOMAC Global
Maximum follow-up: 8 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Blinding of participants? Unclear risk It was unclear if method used to blind par-
ticipants was appropriate
Blinding of health care provider(s) Unclear risk Physicians were not explicitly described as
blinded, so the risk of performance bias was
unclear
Intention-to-treat analysis performed? Pain Unclear risk It was unclear whether all participants ran-
domised were also analysed
Intention-to-treat analysis performed?
Function
Unclear risk Not applicable, no function outcome re-
ported
Smith 2003
Methods Randomised controlled trial
2-arm parallel-group design
Trial duration: 24 weeks
Participants 77 participants with knee osteoarthritis were randomised
71 participants were reported at baseline
Number of females: 27 out of 77 (35%)
Mean age: 66.8 years
Interventions Experimental intervention
120mgmethylprednisolone acetate following joint lavage, single intra-articular injection
Control intervention
Treatment duration: 1 day
Normal saline (no dosage) following joint lavage, single intra-articular injection
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Smith 2003 (Continued)
Outcomes Extracted pain outcome: WOMAC Pain
Extracted function outcome: WOMAC Function
Maximum follow-up: 24 weeks
Notes Funding: National Health and Medical Research Council (Australia) Arthritis Founda-
tion of Australia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was computer-
generated by a member of the hospital
pharmacy department, who also prepared
a blinded intra-articular injection”
Allocation concealment (selection bias) Low risk Quote: “Randomization was computer-
generated by a member of the hospital
pharmacy department, who also prepared
a blinded intra-articular injection”
Blinding of participants? Unclear risk It was unclear if method used to blind par-
ticipants was appropriate
Blinding of health care provider(s) Unclear risk It was unclear if method used to blind
healthcare providers was appropriate
Intention-to-treat analysis performed? Pain High risk Quote: “In the event of relapse as defined
above, the last documented outcome vari-
ables were carried forward”. Still, 6 partic-
ipants were excluded (those needing surgi-
cal intervention because of the arthroscopic
findings at baseline)
Intention-to-treat analysis performed?
Function
High risk Quote: “In the event of relapse as defined
above, the last documented outcome vari-
ables were carried forward”. Still, 6 partic-
ipants were excluded (those needing surgi-
cal intervention because of the arthroscopic
findings at baseline)
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Wright 1960
Methods Randomised controlled trial
3-arm parallel-group design
Trial duration: 20 weeks
Participants 38 knees belonging to 25 participants with knee osteoarthritis were randomised
Unclear number of participants with knee osteoarthritis reported at baseline
Number of females: not stated
Mean age: not stated
Interventions Experimental intervention
Intervention (A): 25 mg hydrocortisone acetate (1 ml), 4 intra-articular injections, in-
terval 2 weeks over 6 weeks
Intervention (B): 25 mg hydrocortisone tertiary-butylacetate (1 ml), 4 intra-articular
injections, interval 2 weeks over 6 weeks
Control intervention
1 ml of placebo, 4 intra-articular injections, interval 2 weeks over 6 weeks
Cross-over design, every participant received 3 x 4 injections
Outcomes Only information on adverse events was extracted
Notes There was no extractable data on pain or function
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The order of courses in each pa-
tient was randomized from a master sheet
in which names were entered consecutively.
”
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Blinding of participants? Unclear risk It was unclear if method used to blind par-
ticipants was appropriate
Blinding of health care provider(s) Unclear risk Physicians were not explicitly described as
blinded, so the risk of performance bias was
unclear
Intention-to-treat analysis performed? Pain Unclear risk Did not report extractable pain outcome
data
Intention-to-treat analysis performed?
Function
Unclear risk Did not report extractable function out-
come data excluded in control group
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Yavuz 2012
Methods Randomised controlled trial
4-arm parallel-group design
Trial duration: 12 weeks
Participants 120 participants with knee osteoarthritis were randomised
120 participants were reported at baseline
Number of females: 76 out of 120 (63%)
Mean age: 60.0 years
Interventions Experimental intervention
Intervention (A): 40 mg triamsinolon acetonate (1 ml), single intra-articular injection
Intervention (B): 3 mg betametazone disodium phosphate (1 ml), single intra-articular
injection
Intervention (C): 40 mg methylprednisolone acetate (1 ml), single intra-articular injec-
tion
Control intervention
1 ml 0.9% sodium chloride, single intra-articular injection
Outcomes Extracted pain outcome (A)-(C): Pain overall
Extracted function outcome (A)-(C): Lequesne index
Maximum follow-up: 12 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “A total of 120 eligible patientswith
knee osteoarthritis were included (accord-
ing to their admission date) and random-
ized into four groups.”
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Blinding of participants? Unclear risk It was unclear if participants were blinded
Blinding of health care provider(s) Unclear risk Physicians were not explicitly described as
blinded, so the risk of performance bias was
unclear
Intention-to-treat analysis performed? Pain Unclear risk It was unclear whether all participants ran-
domised were also analysed
Intention-to-treat analysis performed?
Function
Unclear risk It was unclear whether all participants ran-
domised were also analysed
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Young 2001
Methods Randomised controlled trial
2-arm parallel-group design
Trial duration: 4.3 weeks
Participants 41 knees belonging to 40 participants with knee osteoarthritis were randomised
Unclear number of participants with knee osteoarthritis reported at baseline
Number of females: 16
Mean age: 66.5 years
Interventions Experimental intervention
120 mg methylprednisolone acetate, single intra-articular injection
Control intervention
Normal saline (no dosage stated), single intra-articular injection
Outcomes Extracted pain outcome: WOMAC Global
Extracted function outcome: Other function composite
Maximum follow-up: 4.3 weeks
Notes Funding:NationalHealth andMedical ResearchCouncil, TheClive andVeraRamaciotti
Trust, The Rebecca L. Cooper Foundation,University ofNewSouthWales, The Arthritis
Foundation of Australia, The Royal Australasian College of Physicians
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method used to generate random sequence
of allocation was not reported, so the risk
of selection bias was unclear
Allocation concealment (selection bias) Unclear risk Method used to conceal the random se-
quence of allocation was not reported, so
the risk of selection bias was unclear
Blinding of participants? Unclear risk It was unclear if method used to blind par-
ticipants was appropriate
Blinding of health care provider(s) Unclear risk Physicians were not explicitly described as
blinded, so the risk of performance bias was
unclear
Intention-to-treat analysis performed? Pain Unclear risk It was unclear whether all participants ran-
domised were also analysed
Intention-to-treat analysis performed?
Function
Unclear risk It was unclear whether all participants ran-
domised were also analysed
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Zhilyayev 2012
Methods Randomised controlled trial
4-arm parallel-group design
Trial duration: 12 weeks
Participants 209 knees belonging to 112 participants were randomised
Unclear number of participants with knee osteoarthritis reported at baseline
Number of females: not stated
Mean age: not stated
Interventions Experimental intervention
20 mg triamcinolone acetonid plus 10 ml 0.5% procaine, single intra-articular injection
Control intervention
10 ml 0.5% procaine, single intra-articular injection
Outcomes Extracted pain outcome: WOMAC Pain
Maximum follow-up: 12 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “joints were randomized by en-
velopes to one of 4 treatments”
Allocation concealment (selection bias) Unclear risk Quote: “joints were randomized by en-
velopes to one of 4 treatments”
Blinding of participants? Unclear risk It was unclear if method used to blind par-
ticipants was appropriate
Blinding of health care provider(s) Unclear risk Physicians were not explicitly described as
blinded, so the risk of performance bias was
unclear
Intention-to-treat analysis performed? Pain Unclear risk It was unclear whether all participants ran-
domised were also analysed
Intention-to-treat analysis performed?
Function
Unclear risk Not applicable, no function outcome re-
ported
IA: intra-articular
WOMAC: Western Ontario and McMaster Universities Arthritis Index
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdulla 2013 Recent systematic review
Anonymous 1978 Wrong study design
Anonymous 2011 Wrong study design
Arroll 2004 Recent systematic review
Arroll 2005 Wrong study design
Avouac 2010 Recent systematic review
Baker 1969 Active comparator
Bannuru 2013 Wrong study design: Abstract to relevant systematic review, no references listed
Bannuru 2014 Wrong study design: Abstract to relevant systematic review, no references listed
Bannuru 2015 Recent systematic review
Baratham 2010 Wrong outcomes
Bellamy 2005 Recent systematic review
Bellamy 2006 Recent systematic review
Bennell 2012 Wrong study design
Bjordal 2007 Recent systematic review
Blanke 2008 Wrong study design
Bourne 1985 Wrong study design
Brys 2004 Wrong study design
Canillas 2011 Wrong study design
Cats 1979b Wrong study population
Charalambous 2004 Wrong study design
Cheng 2012 Recent systematic review
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(Continued)
Courtney 2009 Wrong study design
Douglas 2012 Wrong study design
Gait 2014 Wrong study design
Garg 2013 Wrong study design: Abstract to relevant systematic review
, no references listed
Garg 2014 Reason for exclusion
Gerlag 2008a Wrong study design
Godwin 2004 Recent systematic review
Habib 2009 Wrong study design
Habib 2010 Wrong study design
Hepper 2009 Reason for exclusion
Hirsch 2013 Reason for exclusion
Ivanov 1981 Wrong comparator
Jarner 1992 Active comparator
Jones 1993 Wrong study design
Jones 2014 Wrong study design
Keagy 1967 Wrong study design
Khitrov 1997 Active comparator
Kizilkaya 2004 Postsurgical setting
Kizilkaya 2005 Postsurgical setting
Koyonos 2009 Postsurgical setting
Krause 1971 Wrong study design
Legre-Boyer 2015 Wrong study design
Lequesne 1970 Wrong study design
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(Continued)
Maricar 2013 Wrong study design: Abstract to relevant systematic review
, no references listed
Maricar 2013c Recent systematic review
Maricar 2014 Wrong study design
McAlindon 2014 Wrong study design
Murdoch 1959 Wrong study design
Murdoch 1959a Wrong study design
Neame 2003 Wrong study design
Nicol 1972 Wrong study design
No named author Wrong study design
No named author a Wrong study design
No named author b Wrong study design
No named author c Wrong study design
Parmigiani 2010 Duplicate reference
Pendleton 2008 Wrong study design
Punzi 2001 Wrong intervention
Rasmussen 1998 Postsurgical setting
Rasmussen 1998a Postsurgical setting
Rasmussen 1998b Postsurgical setting
Reshetov 2000 Wrong comparator
Ronchetti 2001 Active comparator
Roskos 2005 Wrong study design
Saito 1971 Wrong study design
Shah 1967 Wrong comparator
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(Continued)
Sheldon 1973 Wrong study population
Stein 1996 Active comparator
Stitik 2006 Wrong study design
Stojanovic 1969 Wrong study design
Talke 1986 Wrong study design
Van Middelkoop 2013 Wrong study design: Abstract to relevant systematic review
, no references listed
Van Middelkoop 2013a Wrong study design: Abstract to relevant systematic review
, no references listed
Van Middelkoop 2013b Wrong study design
Van Middelkoop 2014 Wrong study design: Abstract to relevant systematic review
, no references listed
Van Middelkoop 2014a Wrong study design: Abstract to relevant systematic review
, no references listed
Wang 1998 Postsurgical setting
Wang 2015 Wrong study design
Wramner 1959 Wrong study design
Yamamoto 1970 Wrong study design
Zhang 2008 Wrong study design
Zhang 2010 Wrong study design
Zuckner 1958 Active comparator
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Characteristics of studies awaiting assessment [ordered by study ID]
Ellis 2011
Methods Randomised controlled trial
2-arm parallel-group design
Trial duration: 12 weeks
Participants 16 participants with knee osteoarthritis were randomised
Interventions Experimental intervention
3-month exercise program plus 40 mg triamcinolone mixed with 4 ml 1% lidocaine, single intra-articular injection
Control intervention
3-month exercise program plus 1 ml normal saline mixed with 4 ml 1% lidocaine, single intra-articular injection
Outcomes Maximum follow-up: 12 weeks
Outcome data (KOOS pain and function, WOMAC pain and function) not extractable
Notes
Friedman 1978
Methods Unclear
Participants Unclear
Interventions Unclear
Outcomes Outcome data not extractable
Notes
Hall 2013
Methods Randomised controlled trial
2-arm parallel-group design
Participants 25 participants with knee osteoarthritis were randomised
Interventions Experimental intervention
40 mg methylprednisolone acetate, single intra-articular injection
Control intervention
saline, single intra-articular injection
Cross-over design: Every participant received 1 injection each
Outcomes Maximum follow-up: 1 week
Outcome data (WOMAC pain, pain overall, ICOAP questionnaire, ultrasound examination) not extractable
Notes
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Hall 2014
Methods Randomised controlled trial
2-arm parallel-group design
Participants 25 participants with knee osteoarthritis were randomised
Interventions Experimental intervention
40 mg methylprednisolone acetate, single intra-articular injection
Control intervention
saline, single intra-articular injection
Cross-over design: Every participant received 1 injection each
Outcomes Maximum follow-up: 1 week
Outcome data (WOMAC pain, pain overall, ICOAP questionnaire, ultrasound examination) not extractable
Notes
Motyl 2013
Methods Measurement reliability study on participants later taking part in a randomised controlled trial for intra-articular
corticosteroid injection in knee osteoarthritis
Participants 15 participants with knee osteoarthritis
Interventions Unclear
Data for the study was collected before the intra-articular injection
Outcomes Outcome data not extractable
Notes
Motyl 2013a
Methods Measurement reliability study on participants later taking part in a randomised controlled trial for intra-articular
corticosteroid injection in knee osteoarthritis
Participants 15 participants with knee osteoarthritis
Interventions Unclear
Data for the study was collected before the intra-articular injection
Outcomes Outcome data not extractable
Notes
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O’Neill 2014
Methods Open-label clinical trial
Participants 100 participants with knee osteoarthritis
Interventions Experimental intervention
Corticosteroid, single intra-articular injection, type and dosage of corticosteroid unclear
The study analysed the changes in MRI scans before and after the intra-articular corticosteroid injection. All partic-
ipants received the experimental intervention, there was no control group
Outcomes Outcome data not extractable
Notes
Raynauld 1999
Methods Randomised controlled trial
2-arm parallel-group design
Participants 80 participants with knee osteoarthritis were randomised
Interventions Experimental intervention
40 mg triamcinolone hexacetonide, 8 intra-articular injections, 3 months interval
Control intervention
Placebo, 8 intra-articular injections, 3 months interval
Outcomes Outcome data (pain overall, WOMAC) not extractable
Notes
Rezende 2012
Methods Randomised controlled trial
2-arm parallel-group design
Participants 104 participants with knee osteoarthritis were randomised
Interventions Experimental intervention
20 mg of hexacetonide triamcinolone plus 6 ml of hylan GF-20, single intra-articular injection
Control intervention
6 ml of hylan GF-20, single intra-articular injection
Outcomes Maximum follow-up: 24 weeks
Outcome data (VAS, WOMAC, and Lequesne) not extractable
Notes
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Singh 1996
Methods Unclear
Participants Unclear
Interventions Unclear
Outcomes Outcome data not extractable
Notes
ICOAP: Intermittent and Constant Osteoarthritis Pain
KOOS: Knee Injury and Osteoarthritis Outcome Score
MRI: magnetic resonance imaging
VAS: visual analogue scale
WOMAC: Western Ontario and McMaster Universities Arthritis Index
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D A T A A N D A N A L Y S E S
Comparison 1. Pain
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain - Main 26 1749 Std. Mean Difference (Random, 95% CI) -0.40 [-0.58, -0.22]
2 Pain - Timepoints 26 Std. Mean Difference (Random, 95% CI) Subtotals only
2.1 Pain- 1-2 week 16 1041 Std. Mean Difference (Random, 95% CI) -0.48 [-0.70, -0.27]
2.2 Pain- 4-6 week 22 1529 Std. Mean Difference (Random, 95% CI) -0.41 [-0.61, -0.21]
2.3 Pain- 3 months 18 1233 Std. Mean Difference (Random, 95% CI) -0.22 [-0.44, 4.12]
2.4 Pain- 6 months 7 526 Std. Mean Difference (Random, 95% CI) -0.07 [-0.25, 0.11]
Comparison 2. Function
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Function - Main 15 1014 Std. Mean Difference (Random, 95% CI) -0.33 [-0.56, -0.09]
2 Function - Timepoints 15 Std. Mean Difference (Random, 95% CI) Subtotals only
2.1 Function - 1-2 weeks 10 763 Std. Mean Difference (Random, 95% CI) -0.43 [-0.72, -0.14]
2.2 Function - 4-6 weeks 12 818 Std. Mean Difference (Random, 95% CI) -0.36 [-0.63, -0.09]
2.3 Function - 3 months 11 800 Std. Mean Difference (Random, 95% CI) -0.13 [-0.37, 0.10]
2.4 Function - 6 months 4 328 Std. Mean Difference (Random, 95% CI) 0.06 [-0.16, 0.28]
Comparison 3. Quality of life
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Quality of life - Main 2 184 Std. Mean Difference (Random, 95% CI) -0.01 [-0.30, 0.28]
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Comparison 4. Number of participants experiencing any adverse event
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of participants
experiencing any adverse event
- Main
2 84 Risk Ratio (IV, Random, 95% CI) 0.89 [0.64, 1.23]
Comparison 5. Number of participants who withdraw because of adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of participants who
with draw because of adverse
events -Main
2 204 Risk Ratio (IV, Random, 95% CI) 0.33 [0.05, 2.07]
Comparison 6. Number of participants experiencing any serious adverse event
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of participants
experiencing any serious
adverse event - Main
5 331 Risk Ratio (IV, Random, 95% CI) 0.63 [0.15, 2.67]
Comparison 7. Joint space narrowing
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Joint space narrowing - Main 1 68 Std. Mean Difference (Random, 95% CI) -0.02 [-0.49, 0.46]
71Intra-articular corticosteroid for knee osteoarthritis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.1. Comparison 1 Pain, Outcome 1 Pain - Main.
Review: Intra-articular corticosteroid for knee osteoarthritis
Comparison: 1 Pain
Outcome: 1 Pain - Main
Study or subgroup IA Corticosteroid Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Beyaz 2012 25 25 -0.68667 (0.291396) 3.8 % -0.69 [ -1.26, -0.12 ]
Campos 2013 52 -0.4102612 (0.1991779) 51 4.8 % -0.41 [ -0.80, -0.02 ]
Castro 2007 32 30 0.153865 (0.25452) 4.2 % 0.15 [ -0.34, 0.65 ]
Cederlof 1966 26 25 0.343675 (0.443639) 2.6 % 0.34 [ -0.53, 1.21 ]
Chao 2010 34 -0.8324666 (0.2550403) 33 4.2 % -0.83 [ -1.33, -0.33 ]
Di Sante 2012 20 -1.269434 (0.3481429) 20 3.3 % -1.27 [ -1.95, -0.59 ]
Dieppe 1980 12 -0.8378893 (0.4273436) 12 2.7 % -0.84 [ -1.68, 0.00 ]
Friedman 1980 17 17 -0.06448 (0.343092) 3.3 % -0.06 [ -0.74, 0.61 ]
Fri as 2004 103 103 0 (0.1396861) 5.4 % 0.0 [ -0.27, 0.27 ]
Gaffney 1995 42 -0.0516039 (0.2182551) 42 4.6 % -0.05 [ -0.48, 0.38 ]
Grecomoro 1992 20 20 0.2 (0.3170589) 3.6 % 0.20 [ -0.42, 0.82 ]
Henriksen 2015 50 -0.0392837 (0.2000197) 50 4.8 % -0.04 [ -0.43, 0.35 ]
Jones 1996 30 -0.9257629 (0.2721303) 30 4.0 % -0.93 [ -1.46, -0.39 ]
Lyons 2005 10 -0.566251 (0.4570631) 10 2.5 % -0.57 [ -1.46, 0.33 ]
Miller 1958 37 -0.2151739 (0.3313255) 36 3.4 % -0.22 [ -0.86, 0.43 ]
NCT00414427 33 -0.8803853 (0.2562751) 34 4.2 % -0.88 [ -1.38, -0.38 ]
Ozturk 2006 23 -0.1368758 (0.2921525) 24 3.8 % -0.14 [ -0.71, 0.44 ]
Petrella 2015 34 32 -0.0355 (0.2463161) 4.3 % -0.04 [ -0.52, 0.45 ]
Popov 1989 19 -1.088324 (0.4184004) 11 2.7 % -1.09 [ -1.91, -0.27 ]
Ravaud 1999 49 -0.4619007 (0.2061198) 49 4.7 % -0.46 [ -0.87, -0.06 ]
Raynauld 2003 33 0.1177483 (0.2464029) 33 4.3 % 0.12 [ -0.37, 0.60 ]
Schue 2011 5 -0.207736 (0.6144019) 5 1.7 % -0.21 [ -1.41, 1.00 ]
Smith 2003 38 -0.3261666 (0.2395615) 33 4.4 % -0.33 [ -0.80, 0.14 ]
Yavuz 2012 90 30 -1.53523 (0.234898) 4.4 % -1.54 [ -2.00, -1.07 ]
Young 2001 21 -0.3845994 (0.3154607) 20 3.6 % -0.38 [ -1.00, 0.23 ]
-2 -1 0 1 2
Favours corticosteroid Favours control
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(. . . Continued)
Study or subgroup IA Corticosteroid Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Zhilyayev 2012 67 -0.4685471 (0.1873348) 52 4.9 % -0.47 [ -0.84, -0.10 ]
Total (95% CI) 922 827 100.0 % -0.40 [ -0.58, -0.22 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 78.14, df = 25 (P<0.00001); I2 =68%
Test for overall effect: Z = 4.29 (P = 0.000018)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours corticosteroid Favours control
Analysis 1.2. Comparison 1 Pain, Outcome 2 Pain - Timepoints.
Review: Intra-articular corticosteroid for knee osteoarthritis
Comparison: 1 Pain
Outcome: 2 Pain - Timepoints
Study or subgroup IA Corticosteroid Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 Pain- 1-2 week
Beyaz 2012 25 25 -0.83381 (0.295368) 6.1 % -0.83 [ -1.41, -0.25 ]
Campos 2013 52 52 -0.61535 (0.200793) 8.0 % -0.62 [ -1.01, -0.22 ]
Cederlof 1966 26 25 -0.33873 (0.356857) 5.1 % -0.34 [ -1.04, 0.36 ]
Di Sante 2012 20 20 -0.27 (0.317743) 5.7 % -0.27 [ -0.89, 0.35 ]
Dieppe 1980 12 12 -0.83789 (0.427344) 4.2 % -0.84 [ -1.68, 0.00 ]
Friedman 1980 17 17 -0.4608 (0.3478) 5.3 % -0.46 [ -1.14, 0.22 ]
Gaffney 1995 42 42 -0.28951 (0.21951) 7.6 % -0.29 [ -0.72, 0.14 ]
Grecomoro 1992 20 20 0.4 (0.319539) 5.7 % 0.40 [ -0.23, 1.03 ]
Henriksen 2015 50 50 -0.03928 (0.20002) 8.0 % -0.04 [ -0.43, 0.35 ]
Petrella 2015 34 32 -0.40018 (0.248823) 7.0 % -0.40 [ -0.89, 0.09 ]
-2 -1 0 1 2
Favours corticosteroid Favours control
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(. . . Continued)
Study or subgroup IA Corticosteroid Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Popov 1989 19 11 -1.08832 (0.4184) 4.3 % -1.09 [ -1.91, -0.27 ]
Ravaud 1999 49 -0.6703337 (0.2103553) 49 7.8 % -0.67 [ -1.08, -0.26 ]
Schue 2011 5 5 -0.1244 (0.613101) 2.5 % -0.12 [ -1.33, 1.08 ]
Smith 2003 38 33 -0.21581 (0.238655) 7.2 % -0.22 [ -0.68, 0.25 ]
Yavuz 2012 90 30 -1.509 (0.234594) 7.3 % -1.51 [ -1.97, -1.05 ]
Zhilyayev 2012 67 52 -0.42298 (0.186871) 8.2 % -0.42 [ -0.79, -0.06 ]
Subtotal (95% CI) 566 475 100.0 % -0.48 [ -0.70, -0.27 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 40.31, df = 15 (P = 0.00041); I2 =63%
Test for overall effect: Z = 4.33 (P = 0.000015)
2 Pain- 4-6 week
Beyaz 2012 25 25 -0.688667 (0.291396) 4.5 % -0.69 [ -1.26, -0.12 ]
Campos 2013 52 51 -0.41026 (0.199178) 5.6 % -0.41 [ -0.80, -0.02 ]
Castro 2007 32 30 0.153865 (0.25452) 4.9 % 0.15 [ -0.34, 0.65 ]
Cederlof 1966 26 25 0.343675 (0.443639) 3.0 % 0.34 [ -0.53, 1.21 ]
Chao 2010 34 -0.8324666 (0.2550403) 33 4.9 % -0.83 [ -1.33, -0.33 ]
Di Sante 2012 20 -1.269434 (0.3481429) 20 3.9 % -1.27 [ -1.95, -0.59 ]
Friedman 1980 17 17 -0.06448 (0.343092) 3.9 % -0.06 [ -0.74, 0.61 ]
Fri as 2004 103 103 0 (0.1396861) 6.3 % 0.0 [ -0.27, 0.27 ]
Gaffney 1995 42 -0.0575697 (0.2182642) 42 5.3 % -0.06 [ -0.49, 0.37 ]
Grecomoro 1992 20 20 0.2 (0.317059) 4.2 % 0.20 [ -0.42, 0.82 ]
Jones 1996 30 -0.9257629 (0.2721303) 30 4.7 % -0.93 [ -1.46, -0.39 ]
Lyons 2005 10 10 -0.56625 (0.457063) 2.9 % -0.57 [ -1.46, 0.33 ]
Miller 1958 37 36 -0.21517 (0.331326) 4.0 % -0.22 [ -0.86, 0.43 ]
NCT00414427 33 34 -0.88039 (0.256275) 4.9 % -0.88 [ -1.38, -0.38 ]
Ozturk 2006 23 24 -0.13688 (0.292153) 4.5 % -0.14 [ -0.71, 0.44 ]
Petrella 2015 34 32 -0.0355 (0.246316) 5.0 % -0.04 [ -0.52, 0.45 ]
Ravaud 1999 49 -0.4619007 (0.2061198) 49 5.5 % -0.46 [ -0.87, -0.06 ]
Schue 2011 5 5 -0.20774 (0.614402) 2.0 % -0.21 [ -1.41, 1.00 ]
Smith 2003 38 33 -0.32617 (0.239562) 5.1 % -0.33 [ -0.80, 0.14 ]
Yavuz 2012 90 30 -1.53523 (0.234898) 5.1 % -1.54 [ -2.00, -1.07 ]
Young 2001 21 20 -0.3846 (0.315461) 4.2 % -0.38 [ -1.00, 0.23 ]
Zhilyayev 2012 67 52 -0.46855 (0.187335) 5.7 % -0.47 [ -0.84, -0.10 ]
-2 -1 0 1 2
Favours corticosteroid Favours control
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Study or subgroup IA Corticosteroid Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 808 721 100.0 % -0.41 [ -0.61, -0.21 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 67.24, df = 21 (P<0.00001); I2 =69%
Test for overall effect: Z = 4.05 (P = 0.000051)
3 Pain- 3 months
Beyaz 2012 25 25 -0.68667 (0.291396) 5.5 % -0.69 [ -1.26, -0.12 ]
Campos 2013 47 46 -0.15526 (0.207721) 6.7 % -0.16 [ -0.56, 0.25 ]
Castro 2007 32 30 0.269263 (0.255319) 6.0 % 0.27 [ -0.23, 0.77 ]
Cederlof 1966 26 25 0.40991 (0.396514) 4.2 % 0.41 [ -0.37, 1.19 ]
Chao 2010 30 -0.3170632 (0.2621029) 29 5.9 % -0.32 [ -0.83, 0.20 ]
Friedman 1980 17 17 0.064483 (0.343092) 4.8 % 0.06 [ -0.61, 0.74 ]
Fri as 2004 103 103 0.160396 (0.139913) 7.7 % 0.16 [ -0.11, 0.43 ]
Grecomoro 1992 20 20 0.1 (0.316436) 5.1 % 0.10 [ -0.52, 0.72 ]
Henriksen 2015 50 50 0.094281 (0.200113) 6.9 % 0.09 [ -0.30, 0.49 ]
Lyons 2005 10 10 -1.58842 (0.519697) 3.0 % -1.59 [ -2.61, -0.57 ]
Ozturk 2006 23 24 -0.365 (0.294322) 5.5 % -0.37 [ -0.94, 0.21 ]
Petrella 2015 34 32 0.019364 (0.246302) 6.2 % 0.02 [ -0.46, 0.50 ]
Ravaud 1999 49 -0.2818715 (0.2086496) 49 6.7 % -0.28 [ -0.69, 0.13 ]
Raynauld 2003 33 0.1177483 (0.2464029) 33 6.1 % 0.12 [ -0.37, 0.60 ]
Schue 2011 5 5 -1.16174 (0.672952) 2.1 % -1.16 [ -2.48, 0.16 ]
Smith 2003 38 33 0.004905 (0.237948) 6.3 % 0.00 [ -0.46, 0.47 ]
Yavuz 2012 90 30 -1.25 (0.227075) 6.4 % -1.25 [ -1.70, -0.80 ]
Zhilyayev 2012 14 26 -0.59772 (0.338513) 4.9 % -0.60 [ -1.26, 0.07 ]
Subtotal (95% CI) 646 587 100.0 % -0.22 [ -0.44, 0.00 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 54.06, df = 17 (P<0.00001); I2 =69%
Test for overall effect: Z = 1.96 (P = 0.050)
4 Pain- 6 months
Campos 2013 47 46 -0.18852 (0.207873) 19.0 % -0.19 [ -0.60, 0.22 ]
Henriksen 2015 50 50 0.067957 (0.200059) 20.6 % 0.07 [ -0.32, 0.46 ]
Miller 1958 26 25 0.418611 (0.498642) 3.3 % 0.42 [ -0.56, 1.40 ]
Ozturk 2006 23 24 -0.45625 (0.295733) 9.4 % -0.46 [ -1.04, 0.12 ]
Petrella 2015 34 32 -0.08951 (0.246423) 13.6 % -0.09 [ -0.57, 0.39 ]
Ravaud 1999 49 -0.2053177 (0.2045287) 49 19.7 % -0.21 [ -0.61, 0.20 ]
Smith 2003 38 33 0.223167 (0.238704) 14.4 % 0.22 [ -0.24, 0.69 ]
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(. . . Continued)
Study or subgroup IA Corticosteroid Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 267 259 100.0 % -0.07 [ -0.25, 0.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.42, df = 6 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Chi2 = 10.59, df = 3 (P = 0.01), I2 =72%
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Analysis 2.1. Comparison 2 Function, Outcome 1 Function - Main.
Review: Intra-articular corticosteroid for knee osteoarthritis
Comparison: 2 Function
Outcome: 1 Function - Main
Study or subgroup IA Corticosteroid Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Beyaz 2012 25 25 -1.09887 (0.304267) 6.1 % -1.10 [ -1.70, -0.50 ]
Campos 2013 52 -0.0041622 (0.1970754) 51 7.9 % 0.00 [ -0.39, 0.38 ]
Castro 2007 32 30 0.275871 (0.255377) 6.9 % 0.28 [ -0.22, 0.78 ]
Chao 2010 32 -0.972491 (0.2669457) 31 6.7 % -0.97 [ -1.50, -0.45 ]
Di Sante 2012 20 -0.4867452 (0.321119) 20 5.9 % -0.49 [ -1.12, 0.14 ]
Gaffney 1995 42 42 0.208693 (0.218826) 7.5 % 0.21 [ -0.22, 0.64 ]
Henriksen 2015 50 50 0.099827 (0.200127) 7.9 % 0.10 [ -0.29, 0.49 ]
Lyons 2005 10 -1.130546 (0.4852872) 10 3.8 % -1.13 [ -2.08, -0.18 ]
Petrella 2015 33 33 0.006267 (0.246184) 7.1 % 0.01 [ -0.48, 0.49 ]
Popov 1989 19 -1.088324 (0.4184004) 11 4.6 % -1.09 [ -1.91, -0.27 ]
Ravaud 1999 49 -0.3433526 (0.2039811) 49 7.8 % -0.34 [ -0.74, 0.06 ]
Raynauld 2003 33 33 0.06595 (0.246252) 7.1 % 0.07 [ -0.42, 0.55 ]
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(. . . Continued)
Study or subgroup IA Corticosteroid Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Smith 2003 38 33 -0.31211 (0.239426) 7.2 % -0.31 [ -0.78, 0.16 ]
Yavuz 2012 90 -0.8096383 (0.2178688) 30 7.6 % -0.81 [ -1.24, -0.38 ]
Young 2001 21 -0.1579081 (0.3129516) 20 6.0 % -0.16 [ -0.77, 0.46 ]
Total (95% CI) 546 468 100.0 % -0.33 [ -0.56, -0.09 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 45.88, df = 14 (P = 0.00003); I2 =69%
Test for overall effect: Z = 2.70 (P = 0.0069)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Function, Outcome 2 Function - Timepoints.
Review: Intra-articular corticosteroid for knee osteoarthritis
Comparison: 2 Function
Outcome: 2 Function - Timepoints
Study or subgroup IA Corticosteroid Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 Function - 1-2 weeks
Beyaz 2012 25 -1.367485 (0.3154034) 25 8.6 % -1.37 [ -1.99, -0.75 ]
Campos 2013 52 52 -0.6479 (0.20129) 11.3 % -0.65 [ -1.04, -0.25 ]
Di Sante 2012 20 0.1365441 (0.3166154) 20 8.6 % 0.14 [ -0.48, 0.76 ]
Gaffney 1995 42 42 -5E-8 (0.218218) 10.9 % 0.00 [ -0.43, 0.43 ]
Henriksen 2015 50 0.0998268 (0.2001271) 50 11.3 % 0.10 [ -0.29, 0.49 ]
Petrella 2015 34 -0.3737276 (0.2485014) 32 10.2 % -0.37 [ -0.86, 0.11 ]
Popov 1989 19 -1.088324 (0.4184004) 11 6.6 % -1.09 [ -1.91, -0.27 ]
Ravaud 1999 49 -0.3461974 (0.204095) 49 11.2 % -0.35 [ -0.75, 0.05 ]
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(. . . Continued)
Study or subgroup IA Corticosteroid Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Smith 2003 38 33 -0.17322 (0.238404) 10.4 % -0.17 [ -0.64, 0.29 ]
Yavuz 2012 90 -0.8881221 (0.2192932) 30 10.9 % -0.89 [ -1.32, -0.46 ]
Subtotal (95% CI) 419 344 100.0 % -0.43 [ -0.72, -0.14 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 32.02, df = 9 (P = 0.00020); I2 =72%
Test for overall effect: Z = 2.95 (P = 0.0032)
2 Function - 4-6 weeks
Beyaz 2012 25 25 -1.098872 (0.304267) 7.6 % -1.10 [ -1.70, -0.50 ]
Campos 2013 52 -0.0041622 (0.1970754) 51 9.8 % 0.00 [ -0.39, 0.38 ]
Castro 2007 32 30 0.275871 (0.255377) 8.6 % 0.28 [ -0.22, 0.78 ]
Chao 2010 32 31 -0.97491 (0.2669457) 8.4 % -0.97 [ -1.50, -0.45 ]
Di Sante 2012 20 20 -0.48675 (0.321119) 7.3 % -0.49 [ -1.12, 0.14 ]
Gaffney 1995 42 42 0.208693 (0.218826) 9.4 % 0.21 [ -0.22, 0.64 ]
Lyons 2005 10 -1.130546 (0.4852872) 10 4.8 % -1.13 [ -2.08, -0.18 ]
Petrella 2015 33 33 0.006267 (0.2461836) 8.8 % 0.01 [ -0.48, 0.49 ]
Ravaud 1999 49 -0.3433526 (0.2039811) 49 9.7 % -0.34 [ -0.74, 0.06 ]
Smith 2003 38 33 -0.31211 (0.239426) 8.9 % -0.31 [ -0.78, 0.16 ]
Yavuz 2012 90 -0.8096383 (0.2178688) 30 9.4 % -0.81 [ -1.24, -0.38 ]
Young 2001 21 -0.1579081 (0.3129516) 20 7.5 % -0.16 [ -0.77, 0.46 ]
Subtotal (95% CI) 444 374 100.0 % -0.36 [ -0.63, -0.09 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 36.55, df = 11 (P = 0.00014); I2 =70%
Test for overall effect: Z = 2.66 (P = 0.0079)
3 Function - 3 months
Beyaz 2012 25 25 -1.03859 (0.302053) 7.7 % -1.04 [ -1.63, -0.45 ]
Campos 2013 47 46 -0.0017 (0.2074024) 10.5 % 0.00 [ -0.41, 0.40 ]
Castro 2007 32 30 0.38238 (0.256519) 9.0 % 0.38 [ -0.12, 0.89 ]
Chao 2010 25 29 -0.3785 (0.275428) 8.4 % -0.38 [ -0.92, 0.16 ]
Henriksen 2015 50 0.0083189 (0.2000009) 50 10.7 % 0.01 [ -0.38, 0.40 ]
Lyons 2005 10 -0.2928758 (0.4498696) 10 4.9 % -0.29 [ -1.17, 0.59 ]
Petrella 2015 34 0.0596708 (0.2463526) 32 9.3 % 0.06 [ -0.42, 0.54 ]
Ravaud 1999 49 0.0550258 (0.2024998) 49 10.6 % 0.06 [ -0.34, 0.45 ]
Raynauld 2003 33 33 0.0659503 (0.246252) 9.3 % 0.07 [ -0.42, 0.55 ]
Smith 2003 38 33 0.168646 (0.23838) 9.5 % 0.17 [ -0.30, 0.64 ]
Yavuz 2012 90 -0.730327 (0.2164402) 30 10.2 % -0.73 [ -1.15, -0.31 ]
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(. . . Continued)
Study or subgroup IA Corticosteroid Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 433 367 100.0 % -0.13 [ -0.37, 0.10 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 26.10, df = 10 (P = 0.004); I2 =62%
Test for overall effect: Z = 1.10 (P = 0.27)
4 Function - 6 months
Campos 2013 47 -0.0657285 (0.2074596) 46 28.5 % -0.07 [ -0.47, 0.34 ]
Petrella 2015 34 -0.0155596 (0.2462999) 32 20.2 % -0.02 [ -0.50, 0.47 ]
Ravaud 1999 49 0.0082512 (0.2024608) 49 29.9 % 0.01 [ -0.39, 0.41 ]
Smith 2003 38 33 0.373922 (0.240069) 21.3 % 0.37 [ -0.10, 0.84 ]
Subtotal (95% CI) 168 160 100.0 % 0.06 [ -0.16, 0.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.24, df = 3 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Chi2 = 9.57, df = 3 (P = 0.02), I2 =69%
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Analysis 3.1. Comparison 3 Quality of life, Outcome 1 Quality of life - Main.
Review: Intra-articular corticosteroid for knee osteoarthritis
Comparison: 3 Quality of life
Outcome: 1 Quality of life - Main
Study or subgroup IA Corticosteroid Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Gaffney 1995 42 42 0 (0.218218) 45.7 % 0.0 [ -0.43, 0.43 ]
Henriksen 2015 50 50 -0.01571 (0.200003) 54.3 % -0.02 [ -0.41, 0.38 ]
Total (95% CI) 92 92 100.0 % -0.01 [ -0.30, 0.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Number of participants experiencing any adverse event, Outcome 1 Number of
participants experiencing any adverse event - Main.
Review: Intra-articular corticosteroid for knee osteoarthritis
Comparison: 4 Number of participants experiencing any adverse event
Outcome: 1 Number of participants experiencing any adverse event - Main
Study or subgroup IA Corticosteroid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Petrella 2015 21/33 24/33 98.9 % 0.88 [ 0.63, 1.22 ]
Wright 1960 1/9 0/9 1.1 % 3.00 [ 0.14, 65.16 ]
Total (95% CI) 42 42 100.0 % 0.89 [ 0.64, 1.23 ]
Total events: 22 (IA Corticosteroid), 24 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.61, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Number of participants who withdraw because of adverse events, Outcome 1
Number of participants who with draw because of adverse events -Main.
Review: Intra-articular corticosteroid for knee osteoarthritis
Comparison: 5 Number of participants who withdraw because of adverse events
Outcome: 1 Number of participants who with draw because of adverse events -Main
Study or subgroup IA Corticosteroid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Campos 2013 0/52 1/52 33.0 % 0.33 [ 0.01, 8.00 ]
Henriksen 2015 1/50 3/50 67.0 % 0.33 [ 0.04, 3.10 ]
Total (95% CI) 102 102 100.0 % 0.33 [ 0.05, 2.07 ]
Total events: 1 (IA Corticosteroid), 4 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Number of participants experiencing any serious adverse event, Outcome 1
Number of participants experiencing any serious adverse event - Main.
Review: Intra-articular corticosteroid for knee osteoarthritis
Comparison: 6 Number of participants experiencing any serious adverse event
Outcome: 1 Number of participants experiencing any serious adverse event - Main
Study or subgroup IA Corticosteroid Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Henriksen 2015 1/50 3/50 42.1 % 0.33 [ 0.04, 3.10 ]
Lyons 2005 0/10 0/10 Not estimable
Ozturk 2006 0/23 0/24 Not estimable
Petrella 2015 2/33 2/33 57.9 % 1.00 [ 0.15, 6.68 ]
Ravaud 1999 0/49 0/49 Not estimable
Total (95% CI) 165 166 100.0 % 0.63 [ 0.15, 2.67 ]
Total events: 3 (IA Corticosteroid), 5 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.54, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 Joint space narrowing, Outcome 1 Joint space narrowing - Main.
Review: Intra-articular corticosteroid for knee osteoarthritis
Comparison: 7 Joint space narrowing
Outcome: 1 Joint space narrowing - Main
Study or subgroup IA Corticosteroid Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Raynauld 2003 34 34 -0.0184 (0.242541) 100.0 % -0.02 [ -0.49, 0.46 ]
Total (95% CI) 34 34 100.0 % -0.02 [ -0.49, 0.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Stratified analyses: Pain
Variable Number of
studies
N of partici-
pants corticos-
teroids
N of partici-
pants control
Pain intensity
SMD (95% CI)
Heterogeneity I
2 (%)
P value*
All trials 26 922 827 -0.40 (-0.58 to -
0.22)
68%
Allocation concealment 0.15
Adequate 2 88 83 -0.16 (-0.46 to 0.
14)
0%
Inadequate or
unclear
24 834 744 -0.42 (-0.62 to -
0.22)
69%
Blinding of participants 0.64
Adequate 6 220 218 -0.34 (-0.61 to -
0.06)
49%
Inadequate or
unclear
20 702 609 -0.42 (-0.65 to -
0.19)
72%
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Table 1. Stratified analyses: Pain (Continued)
Blinding of therapists 0.45
Adequate 3 92 92 -0.24 (-0.66 to 0.
17)
44%
Inadequate or
unclear
23 830 735 -0.42 (-0.62 to -
0.22)
70%
Intention-to-treat analysis 0.29
Yes 9 236 233 -0.26 (-0.57 to 0.
06)
59%
No or unclear 17 686 594 -0.47 (-0.69 to -
0.24)
71%
Type of control intervention 0.08
Sham injection 19 614 526 -0.50 (-0.72 to -
0.28)
65%
No intervention 7 284 280 -0.18 (-0.47 to 0.
11)
63%
Funding independent of industry 0.80
Yes 11 341 333 -0.37 (-0.55 to -
0.18)
26%
No or unclear 15 581 494 -0.41 (-0.70 to -
0.12)
78%
Trial size 0.05
≥ 50 per trial
group
3 205 204 -0.13 (-0.37 to 0.
12)
34%
< 50 per trial
group
23 717 623 -0.44 (-0.65 to -
0.24)
67%
Trial size 0.013
≥ 100 per trial
group
1 103 103 0.00 (-0.27 to 0.
27)
N/A
< 100 per trial
group
25 819 724 -0.42 (-0.61 to -
0.23)
66%
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Table 1. Stratified analyses: Pain (Continued)
Publication type 0.93
Full journal arti-
cle
22 785 706 -0.40 (-0.61 to -
0.20)
70%
Other type or
unpublishedma-
terial
4 137 121 -0.38 (-0.84 to -
0.08)
65%
Ultrasound guidance of injections 0.71
Yes 2 70 70 -0.62 (-1.83 to 0.
58)
89%
No or unclear 24 852 757 -0.39 (-0.57 to -
0.20)
67%
Use of local anaesthetic 0.41
Yes 5 172 157 -0.55 (-0.93 to -
0.16)
62%
No or unclear 21 750 670 -0.36 (-0.57 to -
0.15)
70%
Concomitant viscosupplementation 0.08
Yes 4 129 127 -0.16 (-0.42 to 0.
09)
4%
No or unclear 22 793 700 -0.46 (-0.67 to -
0.25)
71%
Concomitant joint lavage ≤ 0.001
Yes 4 197 187 -0.06 (-0.26 to 0.
15)
0%
No or unclear 26 725 640 -0.57 (-0.78 to -
0.35)
72%
Use of crystalline preparation 0.82
Yes 18 623 562 -0.47 (-0.69 to -
0.24)
72%
No or unclear 12 299 265 -0.52 (-0.90 to -
0.14)
76%
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Table 1. Stratified analyses: Pain (Continued)
Prednisolone equivalence dose 0.53
≥ 50 mg 17 520 470 -0.55 (-0.85 to -
0.25)
80%
< 50 mg 13 402 357 -0.43 (-0.66 to -
0.20)
56%
Number of randomised comparisons are shown in “number of studies” for stratified analyses according to use of lavage as co-intervention,
crystalline preparation, prednisolone equivalence. *P value for interaction. N/A: not available.
CI: confidence interval
SMD: standardised mean difference
Table 2. Stratified analyses: Function
Variable Number of
studies
N of partici-
pants corticos-
teroids
N of partici-
pants control
Function SMD
(95% CI)
Heterogeneity I
2 (%)
P value*
All trials 15 546 468 -0.33 (-0.56 to -
0.09)
69%
Allocation concealment 0.25
Adequate 2 88 83 -0.09 (-0.49 to 0.
32)
43%
Inadequate or
unclear
13 458 385 -0.37 (-0.64 to -
0.10)
72%
Blinding of participants 0.97
Adequate 5 201 199 -0.32 (-0.82 to 0.
18)
83%
Inadequate or
unclear
10 345 269 -0.33 (-0.59 to -
0.07)
58%
Blinding of therapists 0.78
Adequate 2 75 75 -0.48 (-1.65 to 0.
70)
91%
Inadequate or
unclear
13 471 393 -0.31 (-0.55 to -
0.06)
66%
Intention-to-treat analysis 0.49
86Intra-articular corticosteroid for knee osteoarthritis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Stratified analyses: Function (Continued)
Yes 5 161 159 -0.21 (-0.59 to 0.
17)
62%
No or unclear 10 385 309 -0.38 (-0.69 to -
0.07)
73%
Type of control intervention 0.031
Sham injection 11 409 334 -0.45 (-0.74 to -
0.15)
73%
No intervention 4 137 134 -0.01 (-0.27 to 0.
25)
13%
Funding independent of industry 0.73
Yes 9 310 302 -0.36 (-0.66 to -
0.07)
68%
No or unclear 6 236 166 -0.27 (-0.71 to 0.
16)
76%
Trial size 0.023
≥ 50 per trial
group
2 102 101 0.05 (-0.23 to 0.
32)
0%
< 50 per trial
group
13 444 367 -0.40 (-0.67 to -
0.13)
70%
Trial size N/A
≥ 100 per trial
group
0 0 0 N/A N/A
< 100 per trial
group
15 546 468 -0.33 (-0.56 to -
0.09)
69%
Publication type 0.023
Full journal arti-
cle
14 514 438 -0.37 (-0.61 to -
0.13)
68%
Other type or
unpublishedma-
terial
1 32 30 0.28 (-0.22 to 0.
78)
N/A
Ultrasound guidance of injections 0.49
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Table 2. Stratified analyses: Function (Continued)
Yes 2 70 70 -0.14 (-0.70 to 0.
43)
58%
No or unclear 13 476 398 -0.36 (-0.62 to -
0.09)
71%
Use of local anaesthetic 0.34
Yes 4 105 105 -0.60 (-1.25 to 0.
05)
78%
No or unclear 11 441 363 -0.25 (-0.51 to 0.
00)
68%
Concomitant viscosupplementation 0.06
Yes 2 85 84 -0.00 (-0.30 to 0.
30)
0%
No or unclear 13 461 384 -0.39 (-0.66 to -
0.12)
72%
Concomitant joint lavage 0.18
Yes 3 94 84 -0.13 (-0.55 to 0.
28)
48%
No or unclear 16 452 384 -0.46 (-0.71 to -
0.21)
70%
Use of crystalline preparation 0.66
Yes 12 365 319 -0.37 (-0.66 to -
0.08)
73%
No or unclear 7 181 149 -0.47 (-0.83 to -
0.11)
61%
Prednisolone equivalence dose 0.16
≥ 50 mg 12 328 277 -0.52 (-0.83 to -
0.20)
74%
< 50 mg 7 218 191 -0.22 (-0.48 to 0.
05)
47%
Number of randomised comparisons are shown in “number of studies” for stratified analyses according to use of lavage as co-intervention,
crystalline preparation, prednisolone equivalence. *P value for interaction. N/A: not available.
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CI: confidence interval
SMD: standardised mean difference
A P P E N D I C E S
Appendix 1. MEDLINE and PubMed search strategies
MEDLINE* PubMed†
Search line Search Terms No. citations Search line Search Terms No. citations
1 *Adrenal Cortex
Hormones/ or *17-
Hydroxycorticos-
teroids/ or *11-Hy-
droxycorticosteroids/
or *Hydroxycorticos-
teroids/ or *Ketos-
teroids/ or *17-Ke-
tosteroids/ or *An-
drostenedione/
or *Prednisolone/ or
*Glucocorticoids/ or
*Triamcinolone Ace-
tonide/ or *Hydro-
cortisone/ or *corti-
sone/
104853 1 ((((((osteoarthritis*[tw]
OR osteoarthro*[tw]
OR gonarthriti*[tw]
OR gonarthro*[tw]
OR coxarthriti*[tw]
OR coxarthro*[tw] OR
arthros*[tw] OR arthrot*[tw]
OR ((knee*[tw] OR hip[tw]
OR hips[tw] OR joint*[tw])
near/3 (pain*[tw] OR
ache[tw] OR aches[tw] OR
aching[tw] OR achy[tw]
OR discomfort*[tw])
) OR ((knee*[tw] OR
hip[tw] OR hips[tw] OR
joint*[tw]) near/3 stiff*[tw])
))) AND ((adrenal cortex
hormone*[tw] OR adrenal
cortical hormone*[tw]
OR adrenal steroid*[tw]
OR adrenocortical hor-
mone*[tw] OR adrenocorti-
cal steroid*[tw] OR adreno-
corticalsteroid*[tw] OR
adrenocorticosteroid*[tw]
OR cortical steroid*[tw]
OR cortico-steroid*[tw]
OR corticoid*[tw] OR
corticosteroid*[tw] OR der-
mocortico-steroid*[tw] OR
dermocorticosteroid*[tw]
OR glucocortic*[tw] OR
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(Continued)
hydroxycorticosteroid*[tw]
OR ketosteroid*[tw] OR
androstenedion*[tw] OR
steroid[tw] OR triamci-
nolone hexacetonide[tw]
OR hydrocortison*[tw] OR
prednisolone[tw] OR Pred-
nison*[tw] OR cortison*[tw]
OR Pregnadiene*[tw]))
) AND ((intraartic*[tw]
OR intra-artic*[tw] OR in-
ject*[tw]OR infiltration*[tw]
OR infiltrating[tw]))) AND
(((clinical[Title/Abstract]
AND trial[Title/Abstract])
OR “clinical trial”[tw] OR
“clinical trials”[tw] OR ran-
dom*[tw] OR “therapeutic
use”[tw] OR placebo[tw]
OR sham[tw]))) AND
publisher[sb]
2 (adrenal cortex hor-
mone* or adrenal cor-
tical hormone* or
adrenal steroid* or
adrenocortical
hormone* or adreno-
cortical steroid* or
adrenocorticals-
teroid* or adrenocor-
ticosteroid* or corti-
cal steroid* or cor-
tico-steroid* or cor-
ticoid* or corticos-
teroid* or dermocor-
tico-steroid* or der-
mocorticosteroid* or
glucocortic* or hy-
droxycorticosteroid*
or ketosteroid* or an-
drostenedion*
or steroid or triamci-
nolone hexacetonide
or hydrocortison* or
prednisolone or Pred-
nison* or cortison* or
Pregnadiene*).mp
429888
3 or/1-2 430785
4 (intraartic* or intra-
artic* or inject* or in-
831275
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filtration* or infiltrat-
ing).mp
5 exp osteoarthritis/ 44274
6 (osteoarthriti$ or os-
teoarthro$
or gonarthriti$ or go-
narthro$ or
coxarthriti$ or
coxarthro$).ti,ab,sh
62668
7 (arthros$ or arthrot$)
.ti,ab.
26671
8 ((knee$ or hip$ or
joint$) adj3 (pain$ or
ach$ or discomfort$)
).ti,ab
20156
9 ((knee$ or hip$ or
joint$) adj3 stiff$).ti,
ab.
2914
10 or/5-9 101715
11 (randomized con-
trolled trial or con-
trolled clinical trial).
pt
465958
12 (randomized or
placebo or randomly
or groups or trial).ab.
1916245
13 drug therapy.fs. 1728855
14 or/11-13 3430383
15 random*.ti,ab. 739136
16 or/14-15 3575985
17 and/3-4,10,16 766
18 exp animals/ not hu-
mans.sh.
3974624
19 17 not 18 719
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20 remove duplicates
from 19
713 6
* Search performed at 02nd of February 2015, using the following database in OvidSP: Ovid MEDLINE(R) In-Process & Other Non-
Indexed Citations and Ovid MEDLINE(R) 1946 to Present
† Top-up search in PubMed (http://www.ncbi.nlm.nih.gov/pubmed) at 03rd Februari 2015, to retrieve citations not yet indexed in
OvidSP MEDLINE databases
Appendix 2. EMBASE and CENTRAL search strategies
EMBASE* CENTRAL†
Search line Search Terms No. citations Search line Search Terms No. citations
1 *Adrenal Cortex
Hormones/
or *17-Hydroxy-
corticosteroids/
or *11-Hydroxy-
corticosteroids/
or *Hydroxycor-
ticosteroids/ or
*Ketosteroids/ or
*17-Ketos-
teroids/ or *An-
drostenedione/ or
*Prednisolone/ or
*Glucocor-
ticoids/ or *Tri-
amcinolone Ace-
tonide/ or *Hy-
drocortisone/ or
*cortisone/
191907 #1 MeSH descrip-
tor: [Adrenal Cortex
Hormones] explode
all trees
11438
#2 MeSH descrip-
tor: [Prednisolone]
explode all trees
3470
#3 MeSH
descriptor: [Hydro-
cortisone] explode
all trees
4565
2 (adrenal
cortex hormone*
or adrenal corti-
cal hormone* or
adrenal steroid*
or adrenocortical
hor-
mone* or adreno-
cortical steroid*
or adrenocortical-
s-
teroid* or adreno-
871195 #4 MeSH descrip-
tor: [Triamcinolone
Acetonide] explode
all trees
603
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corticosteroid* or
cortical steroid*
or cortico-
steroid* or corti-
coid* or corticos-
teroid* or dermo-
cortico-steroid*
or dermocorti-
costeroid* or glu-
cocortic* or hy-
droxycor-
ticosteroid* or ke-
tosteroid* or an-
drostenedion* or
steroid or triam-
cinolone hexace-
tonide or hydro-
cortison* or pred-
nisolone or Pred-
nison* or corti-
son* or Pregnadi-
ene*).mp
#5 MeSH
descriptor: [Ketos-
teroids] explode all
trees
962
#6 “adrenal cortex hor-
mone*” or “adrenal
cortical hor-
mone*” or “adrenal
steroid*” or
“adrenocortical hor-
mone*” or “adreno-
cortical steroid*” or
“adrenocorticals-
teroid*” or “adreno-
corticos-
teroid*” or “corti-
cal steroid*” or “cor-
tico-
steroid*” or corti-
coid* or corticos-
teroid* or “dermo-
cortico-steroid*” or
dermocorticos-
teroid* or glucocor-
tic* or hydroxycorti-
costeroid* or ketos-
teroid*
or androstenedion*
or steroid or “tri-
amcinolone hexac-
33629
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(Continued)
etonide” or hydro-
cortison* or pred-
nisolone or Predni-
son* or cortison* or
Pregnadiene*
3 or/1,2 874556
4 (intraartic* or in-
tra-artic* or in-
ject* or infiltra-
tion* or infiltrat-
ing).mp
1069778
5 exp
osteoarthritis/
92440 #7 #1 or #2 or #3 or #
4 or #5 or #6
35680
6 (osteoarthriti$ or
osteoarthro$
or gonarthriti$ or
gonarthro$
or coxarthriti$ or
coxarthro$).ti,ab,
sh
96428 #8 intraartic* or intra-
artic* or inject* or
infiltration* or infil-
trating
52930
7 (arthros$ or
arthrot$).ti,ab.
36551 #9 MeSH descrip-
tor: [Osteoarthritis]
explode all trees
3605
8 ((knee$ or hip$
or joint$) adj3
(pain$ or ach$
or discomfort$)).
ti,ab
29955 #10 (osteoarthritis*
or osteoarthro* or
gonarthriti* or go-
narthro*
or coxarthriti* or
coxarthro* or
arthros* or arthrot*
or ((knee* or hip*
or joint*) near/3
(pain* or ach* or
discomfort*)) or (
(knee* or hip* or
joint*) near/3 stiff*)
)
12050
9 ((knee$ or hip$
or joint$) adj3
stiff$).ti,ab.
4364 #11 #9 or #10 12050
10 or/5-9 160749 #12 #7 and #8 and #11 481
11 exp clinical trial/
or exp evaluation
1017697 #13 #7 and #8 and #11
[in trials]
264
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studies/
12 (clin$ adj25
trial$).ti,ab. or (
(singl$ or doubl$
or
trebl$ or tripl$)
adj25 (blind$ or
mask$)).ti,ab. or
(placebo$ or ran-
dom$ or control$
or prospectiv$ or
volunteer$).ti,ab
4813156
13 (randomized con-
trolled trial
or randomization
or double blind
procedure or sin-
gle blind proce-
dure or method-
ology or follow
up or prospec-
tive study or com-
parative study or
placebo).sh
3749360
14 or/11-13 7670295
15 and/3-4,10,14 1364
16 animals/ not hu-
mans/
1206540
17 15 not 16 1356
18 remove dupli-
cates from 17
1341
* Search performed at 03rd of February 2015, using the following database in OvidSP: Embase Weekly Alerts 2014/07/28-Present,
Embase Classic+Embase 1947 to Present
† Search performed at 03rd of February 2015, using the Cochrane Library of the publisher Wiley at http://onlinelibrary.wiley.com/
cochranelibrary/search.
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WH A T ’ S N E W
Last assessed as up-to-date: 3 February 2015.
Date Event Description
2 November 2015 Amended Typo corrected.
H I S T O R Y
Protocol first published: Issue 1, 1998
Review first published: Issue 2, 2005
Date Event Description
2 September 2015 New citation required and conclusions have changed The review has been updated since last version of 2006.
C O N T R I B U T I O N S O F A U T H O R S
Protocol completion: Jüni, Rutjes, Reichenbach, da Costa.
Acquisition of data: Hari, Rutjes, Fischer, Silletta, da Costa.
Analysis and interpretation of data: Jüni, Hari, Reichenbach, da Costa.
Manuscript preparation: Jüni, Hari, da Costa.
Statistical analysis: Jüni, da Costa.
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S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• NIHR Cochrane Direct Commmission Incentive Award, UK.
This review was supported by a grant from the NIHR, UK (NIHR Cochrane Direct Commmission Incentive Award)
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Types of studies
In the previous version of this Cochrane Review, only RCTs were eligible for inclusion, while in the present review update both RCTs
and quasi-RCTs were eligible.
Types of interventions
In the previous review version, control interventions were both sham intra-articular corticosteroid and active interventions (joint
lavage, intra-articular hyaluronan/hylan, and other intra-articular corticosteroids). In the present review update, the prespecified control
interventions were sham intra-articular corticosteroid and no intervention.
Types of outcome measures
In the previous review version there were eight outcomes: pain, physical function, patient global assessment, joint imaging, adverse
reaction caused by procedure, adverse reaction caused by corticosteroid, adverse reaction caused by toxicity-related withdrawals, total
number of withdrawals and dropouts. In the review update, there were two prespecified primary outcomes and six prespecified secondary
outcomes. Primary outcomes were pain and physical function, and secondary outcomes were quality of life, joint imaging, and the
number of participants who experienced any adverse event, withdrew because of adverse events, and experienced any serious adverse
events.
Search methods for identification of studies
In the previous review version, the following four databases were searched: Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE (including PreMEDLINE), EMBASE, and Current Contents. The electronic searches were supplemented by handsearches
of bibliographic references and abstracts published in conference proceedings or in special issues of specialised journals, and industry
representatives were contacted to request additional studies of their product that could meet eligibility criteria. In the present review
update, we searched the following three databases: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE Ovid and
PubMed platforms, and EMBASE. The electronic searches were supplemented by handsearches of bibliographic references, abstracts
published in conference proceedings, and search of clinical trial registers to identify ongoing or recently concluded trials.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Adrenal Cortex Hormones [∗administration & dosage; adverse effects]; Hyaluronic Acid [adverse effects; analogs & derivatives; thera-
peutic use]; Injections, Intra-Articular; Osteoarthritis, Knee [∗drug therapy; therapy]; Randomized Controlled Trials as Topic; Thera-
peutic Irrigation [methods]
MeSH check words
Humans
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